PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34876569-0 2021 TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway. Cisplatin 25-34 mechanistic target of rapamycin kinase Homo sapiens 98-102 16033649-0 2005 Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Cisplatin 11-20 mechanistic target of rapamycin kinase Homo sapiens 35-39 34643088-8 2022 Finally, an additive effect promoting cell death occurs with a combination of an mTOR inhibitor and cisplatin. Cisplatin 100-109 mechanistic target of rapamycin kinase Homo sapiens 81-85 34876569-11 2021 TTK silencing increased cisplatin sensitivity by activating the mammalian target of rapamycin (mTOR) complex to further suppress cisplatin-induced autophagy in vitro. Cisplatin 24-33 mechanistic target of rapamycin kinase Homo sapiens 64-93 34876569-11 2021 TTK silencing increased cisplatin sensitivity by activating the mammalian target of rapamycin (mTOR) complex to further suppress cisplatin-induced autophagy in vitro. Cisplatin 24-33 mechanistic target of rapamycin kinase Homo sapiens 95-99 34876569-11 2021 TTK silencing increased cisplatin sensitivity by activating the mammalian target of rapamycin (mTOR) complex to further suppress cisplatin-induced autophagy in vitro. Cisplatin 129-138 mechanistic target of rapamycin kinase Homo sapiens 64-93 34876569-11 2021 TTK silencing increased cisplatin sensitivity by activating the mammalian target of rapamycin (mTOR) complex to further suppress cisplatin-induced autophagy in vitro. Cisplatin 129-138 mechanistic target of rapamycin kinase Homo sapiens 95-99 34329824-0 2021 Improved tumor-suppressive effect of OZ-001 combined with cisplatin mediated by mTOR/p70S6K and STAT3 inactivation in A549 human lung cancer cells. Cisplatin 58-67 mechanistic target of rapamycin kinase Homo sapiens 80-84 34329824-4 2021 Moreover, our findings showed that mechanistic target of rapamycin (mTOR), ribosomal protein S6 kinase (p70S6K), and signal transducer and activator of transcription (STAT3) inactivation was required for apoptosis induced by the combination of OZ-001 and cisplatin in in vitro and in vivo experiments. Cisplatin 255-264 mechanistic target of rapamycin kinase Homo sapiens 35-66 34329824-4 2021 Moreover, our findings showed that mechanistic target of rapamycin (mTOR), ribosomal protein S6 kinase (p70S6K), and signal transducer and activator of transcription (STAT3) inactivation was required for apoptosis induced by the combination of OZ-001 and cisplatin in in vitro and in vivo experiments. Cisplatin 255-264 mechanistic target of rapamycin kinase Homo sapiens 68-72 34329824-5 2021 Our results suggest that combined treatment with OZ-001 and cisplatin could potentiate antiproliferative effects via suppression of the mTOR/p70S6K and STAT3 pathways and may be considered a potential therapeutic agent for NSCLC. Cisplatin 60-69 mechanistic target of rapamycin kinase Homo sapiens 136-140 34543857-0 2021 STAT3 contributes to cisplatin resistance, modulating EMT markers, and the mTOR signaling in lung adenocarcinoma. Cisplatin 21-30 mechanistic target of rapamycin kinase Homo sapiens 75-79 34543857-4 2021 It is known that STAT3 phosphorylation at Ser727 by mechanistic target of rapamycin (mTOR) is necessary for its maximal activation, but the crosstalk between STAT3 and mTOR signaling in cisplatin resistance remains elusive. Cisplatin 186-195 mechanistic target of rapamycin kinase Homo sapiens 52-83 34543857-4 2021 It is known that STAT3 phosphorylation at Ser727 by mechanistic target of rapamycin (mTOR) is necessary for its maximal activation, but the crosstalk between STAT3 and mTOR signaling in cisplatin resistance remains elusive. Cisplatin 186-195 mechanistic target of rapamycin kinase Homo sapiens 168-172 34543857-11 2021 Mechanistically, STAT3 partially coordinated the cisplatin resistance phenotype via the mTOR pathway in non-small cell lung cancer. Cisplatin 49-58 mechanistic target of rapamycin kinase Homo sapiens 88-92 34543857-12 2021 Thus, our findings reveal important targets and highlight the significance of the crosstalk between STAT3 and mTOR signaling in cisplatin resistance. Cisplatin 128-137 mechanistic target of rapamycin kinase Homo sapiens 110-114 34427099-0 2021 HDAC3-mediated lncRNA-LOC101928316 contributes to cisplatin resistance in gastric cancer via activating the PI3K-Akt-mTOR pathway. Cisplatin 50-59 mechanistic target of rapamycin kinase Homo sapiens 117-121 34427099-5 2021 Together, the overexpression of HDAC3 mediated LOC101928316 to promote GC resistance to cisplatin by activating the PI3K-Akt-mTOR pathway. Cisplatin 88-97 mechanistic target of rapamycin kinase Homo sapiens 125-129 34261004-5 2021 From a list of differential expressed genes, cisplatin downregulated the cyclin-dependent kinase inhibitor 1 (CDKN1A), tumor necrosis factor (FAS), and sestrin-1 (SESN1) genes responsible for modifying signaling pathways, including the p53, JAK-STAT, FOXO, MAPK, mTOR, P13-AKT, Toll-like receptor (TLR), adipocytokine, and insulin signaling pathways. Cisplatin 45-54 mechanistic target of rapamycin kinase Homo sapiens 263-267 34915755-7 2021 Moreover, Cisplatin-induced activation of mammalian target of rapamycin mTOR and inactivation of AMPK/PI3K/Akt signal pathway, and was coupled with induction of p53 activity and the executioner caspase3 to induce apoptotic renal cell death. Cisplatin 10-19 mechanistic target of rapamycin kinase Homo sapiens 72-76 34298686-5 2021 Moreover, cisplatin-induced autophagy-lysosomal degradation of Exo70 protein by modulating phosphorylation of AMPK and mTOR, thereby reducing the cellular resistance. Cisplatin 10-19 mechanistic target of rapamycin kinase Homo sapiens 119-123 34277781-11 2021 The experiment shows that ROPPIP can up-regulate the expression levels of MMP2, Ki67, and Bcl2 in HTR-8/Svneo cells, down-regulate the expression of caspase-3, promote the proliferation and migration of HTR-8/Svneo cells and inhibit the apoptosis induced by cisplatin, the activation of the phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway may be associated with the function of ROPPIP. Cisplatin 258-267 mechanistic target of rapamycin kinase Homo sapiens 338-367 34277781-11 2021 The experiment shows that ROPPIP can up-regulate the expression levels of MMP2, Ki67, and Bcl2 in HTR-8/Svneo cells, down-regulate the expression of caspase-3, promote the proliferation and migration of HTR-8/Svneo cells and inhibit the apoptosis induced by cisplatin, the activation of the phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway may be associated with the function of ROPPIP. Cisplatin 258-267 mechanistic target of rapamycin kinase Homo sapiens 378-382 34077013-5 2021 The protein levels of p-VEGFR2, VEGFR2, p-Akt, Akt, p-mTOR and mTOR in TPC-1 cells influenced by the treatment of Apatinib combined with cisplatin were examined by Western blot. Cisplatin 137-146 mechanistic target of rapamycin kinase Homo sapiens 54-58 34077013-5 2021 The protein levels of p-VEGFR2, VEGFR2, p-Akt, Akt, p-mTOR and mTOR in TPC-1 cells influenced by the treatment of Apatinib combined with cisplatin were examined by Western blot. Cisplatin 137-146 mechanistic target of rapamycin kinase Homo sapiens 63-67 34077013-8 2021 Apatinib treatment strengthened the anti-tumor influence of cisplatin on TPC-1 cells through downregulating p-VEGFR2, p-Akt and p-mTOR. Cisplatin 60-69 mechanistic target of rapamycin kinase Homo sapiens 130-134 34077013-9 2021 CONCLUSIONS: Apatinib strengthens the anti-tumor influence of cisplatin in thyroid carcinoma through VEGFR2-Akt-mTOR pathway. Cisplatin 62-71 mechanistic target of rapamycin kinase Homo sapiens 112-116 34077027-0 2021 Tormentic acid induces anticancer effects in cisplatin-resistant human cervical cancer cells mediated via cell cycle arrest, ROS production, and targeting mTOR/PI3K/AKT signalling pathway. Cisplatin 45-54 mechanistic target of rapamycin kinase Homo sapiens 155-159 34077027-16 2021 CONCLUSIONS: The outcomes of the present investigation suggest that tormentic acid-induced apoptotic effects in cisplatin-resistant HeLa cells were mediated via cell cycle arrest, ROS production and targeting of mTOR/PI3K/AKT signalling pathway. Cisplatin 112-121 mechanistic target of rapamycin kinase Homo sapiens 212-216 35263216-0 2022 Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis. Cisplatin 35-44 mechanistic target of rapamycin kinase Homo sapiens 160-164 35238281-2 2022 We found that ataxia-telangiectasia mutated (ATM), ataxia-telangiectasia and Rad3-related (ATR) and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) of DNA repair kinases and signal transduction molecules, protein kinase B (AKT)/target mammalian target of rapamycin (mTOR), were significantly phosphorylated in cisplatin-resistant wtEGFR NSCLC cell lines (H358R and A549R) than in their parental cells. Cisplatin 320-329 mechanistic target of rapamycin kinase Homo sapiens 245-274 35238281-2 2022 We found that ataxia-telangiectasia mutated (ATM), ataxia-telangiectasia and Rad3-related (ATR) and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) of DNA repair kinases and signal transduction molecules, protein kinase B (AKT)/target mammalian target of rapamycin (mTOR), were significantly phosphorylated in cisplatin-resistant wtEGFR NSCLC cell lines (H358R and A549R) than in their parental cells. Cisplatin 320-329 mechanistic target of rapamycin kinase Homo sapiens 276-280 35238281-5 2022 The data indicated that the abnormal activation of ATM/ATR/DNA-PKcs kinases and AKT/mTOR pathway might induce wtEGFR NSCLC cell resistance to cisplatin. Cisplatin 142-151 mechanistic target of rapamycin kinase Homo sapiens 84-88 35263216-6 2022 Furthermore, it was discovered that ASF1B activated PI3K/AKT/mTOR signaling to facilitate the DDP resistance of TNBC cells. Cisplatin 94-97 mechanistic target of rapamycin kinase Homo sapiens 61-65 34046349-7 2021 Further investigations showed that miRNA-21 combined with cisplatin caused excessive inactivation of the pI3K/AKT/mTOR/HIF-1alpha signaling pathway in cisplatin-resistant A549/DDP cells. Cisplatin 58-67 mechanistic target of rapamycin kinase Homo sapiens 114-118 33846781-0 2021 Metformin impairs cisplatin resistance effects in A549 lung cancer cells through mTOR signaling and other metabolic pathways. Cisplatin 18-27 mechanistic target of rapamycin kinase Homo sapiens 81-85 35057550-0 2022 Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway. Cisplatin 59-68 mechanistic target of rapamycin kinase Homo sapiens 153-157 35001804-0 2022 Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway. Cisplatin 59-68 mechanistic target of rapamycin kinase Homo sapiens 121-125 34046349-7 2021 Further investigations showed that miRNA-21 combined with cisplatin caused excessive inactivation of the pI3K/AKT/mTOR/HIF-1alpha signaling pathway in cisplatin-resistant A549/DDP cells. Cisplatin 151-160 mechanistic target of rapamycin kinase Homo sapiens 114-118 33717260-12 2021 miR-136-5p overexpression decreased the expression levels of its downstream target ROCK1 and attenuated activity of the Akt/mTOR signaling pathway in cisplatin-treated LSCC and HPSCC cells. Cisplatin 150-159 mechanistic target of rapamycin kinase Homo sapiens 124-128 33908630-0 2021 Cyanidin-3-O-glucoside and cisplatin inhibit proliferation and downregulate the PI3K/AKT/mTOR pathway in cervical cancer cells. Cisplatin 27-36 mechanistic target of rapamycin kinase Homo sapiens 89-93 33073679-0 2021 mTOR Inhibition Ablates Cisplatin-Resistant Salivary Gland Cancer Stem Cells. Cisplatin 24-33 mechanistic target of rapamycin kinase Homo sapiens 0-4 33073679-4 2021 The purpose of this study was to investigate the effect of therapeutic inhibition of mTOR (mechanistic target of rapamycin) on resistance of CSCs to cisplatin, a prototypic platinum-based chemotherapeutic agent. Cisplatin 149-158 mechanistic target of rapamycin kinase Homo sapiens 85-89 33073679-4 2021 The purpose of this study was to investigate the effect of therapeutic inhibition of mTOR (mechanistic target of rapamycin) on resistance of CSCs to cisplatin, a prototypic platinum-based chemotherapeutic agent. Cisplatin 149-158 mechanistic target of rapamycin kinase Homo sapiens 91-122 33073679-8 2021 We observed that cisplatin induced mTOR and S6K1 phosphorylation, increased the number and size of MEC salispheres, and induced Bmi-1 expression and the fraction of CSCs in MEC models in vitro. Cisplatin 17-26 mechanistic target of rapamycin kinase Homo sapiens 35-39 33073679-10 2021 In contrast, mTOR inhibition (e.g., temsirolimus) blocked cisplatin-induced Bmi-1 expression and salisphere formation in vitro. Cisplatin 58-67 mechanistic target of rapamycin kinase Homo sapiens 13-17 33568627-0 2021 BCAT1 decreases the sensitivity of cancer cells to cisplatin by regulating mTOR-mediated autophagy via branched-chain amino acid metabolism. Cisplatin 51-60 mechanistic target of rapamycin kinase Homo sapiens 75-79 33568627-5 2021 The cisplatin-induced up-regulation of BCAT1 decreased the cisplatin sensitivity by regulating autophagy through the mTOR signaling pathway. Cisplatin 4-13 mechanistic target of rapamycin kinase Homo sapiens 117-121 33568627-5 2021 The cisplatin-induced up-regulation of BCAT1 decreased the cisplatin sensitivity by regulating autophagy through the mTOR signaling pathway. Cisplatin 59-68 mechanistic target of rapamycin kinase Homo sapiens 117-121 33568627-6 2021 In addition, branched-chain amino acids or leucine treatment inhibited cisplatin- or BCAT1-mediated autophagy and increased cisplatin sensitivity by activating mTOR signaling in cancer cells. Cisplatin 124-133 mechanistic target of rapamycin kinase Homo sapiens 160-164 33568627-9 2021 These findings demonstrate a new mechanism, revealing that BCAT1 decreases cisplatin sensitivity in cancer cells by inducing mTOR-mediated autophagy via branched-chain amino acid leucine metabolism, providing an attractive pharmacological target to improve the effectiveness of chemotherapy. Cisplatin 75-84 mechanistic target of rapamycin kinase Homo sapiens 125-129 33179318-0 2021 Pseudogene KRT17P3 drives cisplatin resistance of human NSCLC cells by modulating miR-497-5p/mTOR. Cisplatin 26-35 mechanistic target of rapamycin kinase Homo sapiens 93-97 33179318-8 2021 Taken together, our findings indicate that KRT17P3/miR-497-5p/mTOR regulates the chemosensitivity of NSCLC, suggesting a potential therapeutic target for cisplatin-resistant NSCLC patients. Cisplatin 154-163 mechanistic target of rapamycin kinase Homo sapiens 62-66 33362566-0 2020 Berberine Improves Chemo-Sensitivity to Cisplatin by Enhancing Cell Apoptosis and Repressing PI3K/AKT/mTOR Signaling Pathway in Gastric Cancer. Cisplatin 40-49 mechanistic target of rapamycin kinase Homo sapiens 102-106 33391038-0 2020 AMPK/mTOR Signaling in Autophagy Regulation During Cisplatin-Induced Acute Kidney Injury. Cisplatin 51-60 mechanistic target of rapamycin kinase Homo sapiens 5-9 33391038-4 2020 Both mTOR and AMPK have been implicated in the regulation of autophagy in cisplatin-induced AKI. Cisplatin 74-83 mechanistic target of rapamycin kinase Homo sapiens 5-9 33391038-5 2020 Targeting mTOR and/or AMPK may offer effective strategies for kidney protection during cisplatin-mediated chemotherapy. Cisplatin 87-96 mechanistic target of rapamycin kinase Homo sapiens 10-14 33362566-10 2020 Mechanistically, berberine significantly suppressed the PI3K/AKT/mTOR in the BGC-823/DDP and SGC-7901/DDP cells treated with DDP. Cisplatin 85-88 mechanistic target of rapamycin kinase Homo sapiens 65-69 32819590-0 2020 GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway. Cisplatin 56-65 mechanistic target of rapamycin kinase Homo sapiens 149-153 33123242-13 2020 Collectively, the present study indicated that the combined treatment of cisplatin and NVP-BEZ235 displayed synergistic antitumor effects on drug-resistant A549/DDP cells, by which the antiproliferative effects may occur via inhibition of the PI3K/Akt/mTOR signaling pathway and downregulation of drug efflux. Cisplatin 73-82 mechanistic target of rapamycin kinase Homo sapiens 252-256 33575476-0 2021 Metformin enhances anti-cancer effects of cisplatin in meningioma through AMPK-mTOR signaling pathways. Cisplatin 42-51 mechanistic target of rapamycin kinase Homo sapiens 79-83 33575476-8 2021 These results demonstrate metformin enhanced the anti-cancer effect of cisplatin in meningioma in vitro and in vivo, an effect mediated through the activation of AMPK and repression of mTOR signaling pathways. Cisplatin 71-80 mechanistic target of rapamycin kinase Homo sapiens 185-189 33275201-0 2020 Regulation of mTOR by miR-107 to facilitate glioma cell apoptosis and to enhance cisplatin sensitivity. Cisplatin 81-90 mechanistic target of rapamycin kinase Homo sapiens 14-18 33115978-12 2020 Silencing HOXA11-AS can inhibit the c-Met/AKT/mTOR pathway by specifically upregulating miR-454-3p, thus promoting cell apoptosis and enhancing the sensitivity of cisplatin-resistant NPC cells to cisplatin. Cisplatin 163-172 mechanistic target of rapamycin kinase Homo sapiens 46-50 32800561-0 2020 Baicalein enhanced cisplatin sensitivity of gastric cancer cells by inducing cell apoptosis and autophagy via Akt/mTOR and Nrf2/Keap 1 pathway. Cisplatin 19-28 mechanistic target of rapamycin kinase Homo sapiens 114-118 33112540-7 2020 qPCR and western blot revealed that a combination of Sorafenib (10 mumol/L) and cisplatinum (10 mg/L) reduced the transcription and protein expression of autophagy-related AKT and mTOR but increased that of LC3 (P <0.05). Cisplatin 80-91 mechanistic target of rapamycin kinase Homo sapiens 180-184 33112540-8 2020 CONCLUSION: Combining Sorafenib and cisplatinum can effectively induce cell autophagy and reduce cellular proliferation via the PI3K/AKT/mTOR signal pathway.
. Cisplatin 36-47 mechanistic target of rapamycin kinase Homo sapiens 137-141 32593915-8 2020 Several pre-clinical approaches have proven successful in overcoming cisplatin resistance, including specific targeting of PARP, MDM2 or AKT/mTOR combined with cisplatin. Cisplatin 69-78 mechanistic target of rapamycin kinase Homo sapiens 141-145 32599072-9 2020 Combining mTOR inhibition with cisplatin/etoposide decreased PDX tumor volume 96% compared to cisplatin/etoposide alone at 70 days (P<0.002). Cisplatin 94-103 mechanistic target of rapamycin kinase Homo sapiens 10-14 32744675-0 2020 MiR-100 up-regulation enhanced cell autophagy and apoptosis induced by cisplatin in osteosarcoma by targeting mTOR. Cisplatin 71-80 mechanistic target of rapamycin kinase Homo sapiens 110-114 32458975-0 2020 SIK2 Promotes Cisplatin Resistance Induced by Aerobic Glycolysis in Breast Cancer Cells through PI3K/AKT/mTOR Signaling Pathway. Cisplatin 14-23 mechanistic target of rapamycin kinase Homo sapiens 105-109 32608202-0 2020 Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells. Cisplatin 105-114 mechanistic target of rapamycin kinase Homo sapiens 82-86 32608202-1 2020 PURPOSE: The current study aimed to investigate the synergistic antitumor effect of combined treatment with 17-DMAG (HSP90 inhibitor) and NVP-BEZ235 (PI3K/mTOR dual inhibitor) on cisplatin-resistant human bladder cancer cells. Cisplatin 179-188 mechanistic target of rapamycin kinase Homo sapiens 155-159 32608202-11 2020 CONCLUSION: HSP90 inhibitor monotherapy and in combination with the PI3K/mTOR survival pathway inhibitor NVP-BEZ235 shows a synergistic antitumor effect in cisplatin-resistant bladder cancers, eliciting cell cycle arrest at the G1 phase and induction of caspase-dependent apoptotic pathway. Cisplatin 156-165 mechanistic target of rapamycin kinase Homo sapiens 73-77 32458975-10 2020 SIK2 can promote cisplatin resistance caused by aerobic glycolysis of breast cancer cells through PI3K/AKT/mTOR signaling pathway, which may be a new target to improve cisplatin resistance of breast cancer cells. Cisplatin 17-26 mechanistic target of rapamycin kinase Homo sapiens 107-111 32458975-10 2020 SIK2 can promote cisplatin resistance caused by aerobic glycolysis of breast cancer cells through PI3K/AKT/mTOR signaling pathway, which may be a new target to improve cisplatin resistance of breast cancer cells. Cisplatin 168-177 mechanistic target of rapamycin kinase Homo sapiens 107-111 32097729-5 2020 Down-regulation of intracellular ROS attenuated apoptosis and autophagy of TSCC cisplatin-resistant CAL27/CDDP cells by reversing the inhibition of p38MAPK/mTOR pathway. Cisplatin 80-89 mechanistic target of rapamycin kinase Homo sapiens 156-160 32097729-6 2020 Taken together, these findings suggest that down-regulation of intracellular ROS reduces the cytotoxicity of cisplatin by inhibiting apoptosis and autophagy in TSCC cells involving p38MAPK/mTOR mediated pathway. Cisplatin 109-118 mechanistic target of rapamycin kinase Homo sapiens 189-193 31913198-0 2020 miR-21 modulates cisplatin resistance of gastric cancer cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway. Cisplatin 17-26 mechanistic target of rapamycin kinase Homo sapiens 103-107 32368441-9 2020 PI3K/Akt/mTOR pathway was potentially activated in CD133+ MG-63 cells, and involved in the cisplatin resistance of MG-63 cells. Cisplatin 91-100 mechanistic target of rapamycin kinase Homo sapiens 9-13 32368441-13 2020 The decrease of MARK2 restricted the cisplatin resistance of CD133+ MG-63 and MNNG/HOS cells by down regulating the expression of DNA dependent protein kinase catalytic subunit (DNA-PKcs) and inhibiting activity of PI3K/Akt/mTOR signaling pathway, which provides new clues for the osteosarcoma chemotherapy strategy. Cisplatin 37-46 mechanistic target of rapamycin kinase Homo sapiens 224-228 32267053-13 2020 Salicylate hinders OSCC cell growth and sensitizes OSCC cells to CDDP through targeting CSCs and the mTOR signaling pathway. Cisplatin 65-69 mechanistic target of rapamycin kinase Homo sapiens 101-105 31913198-9 2020 GC cells became refractory to the growth inhibition and apoptosis induced by DDP treatment, activation of Akt and mTOR were increased in DDP-resistant GC cells. Cisplatin 137-140 mechanistic target of rapamycin kinase Homo sapiens 114-118 31913198-13 2020 In conclusion, the results demonstrated that miR-21 is associated with DDP resistance in GC cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway, and autophagy inducers could be therapeutic targets for the effective treatment of DDP resistance in GC. Cisplatin 71-74 mechanistic target of rapamycin kinase Homo sapiens 139-143 32323781-10 2020 miR-22 mediated the CDDP resistance of OS cells by inhibiting autophagy and decreasing CDDP-induced autophagy via downregulation of the expression of PI3K, Akt, and mTOR at the mRNA level, and the expression of PI3K, phosphorylated (p)-Akt, and p-mTOR at the protein level. Cisplatin 20-24 mechanistic target of rapamycin kinase Homo sapiens 165-169 31917287-0 2020 TIPE2 suppressed cisplatin resistance by inducing autophagy via mTOR signalling pathway. Cisplatin 17-26 mechanistic target of rapamycin kinase Homo sapiens 64-68 31917287-8 2020 Preconditioning with the mTOR activator 3BDO abrogated TIPE2-mediated depression in cisplatin-evoked autophagy. Cisplatin 84-93 mechanistic target of rapamycin kinase Homo sapiens 25-29 32323781-10 2020 miR-22 mediated the CDDP resistance of OS cells by inhibiting autophagy and decreasing CDDP-induced autophagy via downregulation of the expression of PI3K, Akt, and mTOR at the mRNA level, and the expression of PI3K, phosphorylated (p)-Akt, and p-mTOR at the protein level. Cisplatin 20-24 mechanistic target of rapamycin kinase Homo sapiens 247-251 32323781-10 2020 miR-22 mediated the CDDP resistance of OS cells by inhibiting autophagy and decreasing CDDP-induced autophagy via downregulation of the expression of PI3K, Akt, and mTOR at the mRNA level, and the expression of PI3K, phosphorylated (p)-Akt, and p-mTOR at the protein level. Cisplatin 87-91 mechanistic target of rapamycin kinase Homo sapiens 165-169 32323781-10 2020 miR-22 mediated the CDDP resistance of OS cells by inhibiting autophagy and decreasing CDDP-induced autophagy via downregulation of the expression of PI3K, Akt, and mTOR at the mRNA level, and the expression of PI3K, phosphorylated (p)-Akt, and p-mTOR at the protein level. Cisplatin 87-91 mechanistic target of rapamycin kinase Homo sapiens 247-251 32323781-11 2020 It was also convincingly demonstrated that miR-22 mediates the CDDP resistance of OS by inhibiting autophagy via the PI3K/Akt/mTOR pathway. Cisplatin 63-67 mechanistic target of rapamycin kinase Homo sapiens 126-130 32323781-13 2020 Interestingly, CDDP was demonstrated to induce autophagy by inhibiting the PI3K/Akt/mTOR pathway, whereas the pathway was upregulated in the state of chemoresistance. Cisplatin 15-19 mechanistic target of rapamycin kinase Homo sapiens 84-88 32308804-7 2020 In addition, the combination treatment of PLB and cisplatin resulted in a synergistic inhibition of TSCC viability, apoptosis, and autophagy by increasing intracellular ROS, which may be achieved by activating JNK and inhibiting AKT/mTOR signaling pathways. Cisplatin 50-59 mechanistic target of rapamycin kinase Homo sapiens 233-237 32104214-0 2020 Ghrelin inhibits cisplatin-induced MDA-MB-231 breast cancer cell apoptosis via PI3K/Akt/mTOR signaling. Cisplatin 17-26 mechanistic target of rapamycin kinase Homo sapiens 88-92 32131519-4 2020 Treatment with 3DC2ME reduced the increased Cyto-ID-stained autophagic vesicles and reversed the protein expressions of 5" AMP-activated protein kinase subunit beta-1 (AMPK)/mammalian target of rapamycin (mTOR)-dependent signaling pathway in cisplatin-induced cell death. Cisplatin 242-251 mechanistic target of rapamycin kinase Homo sapiens 174-203 32131519-4 2020 Treatment with 3DC2ME reduced the increased Cyto-ID-stained autophagic vesicles and reversed the protein expressions of 5" AMP-activated protein kinase subunit beta-1 (AMPK)/mammalian target of rapamycin (mTOR)-dependent signaling pathway in cisplatin-induced cell death. Cisplatin 242-251 mechanistic target of rapamycin kinase Homo sapiens 205-209 32323781-0 2020 MicroRNA-22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway. Cisplatin 25-34 mechanistic target of rapamycin kinase Homo sapiens 109-113 32323781-6 2020 The aim of the present study was therefore to investigate whether miR-22 could mediate the CDDP resistance of OS cells by inhibiting autophagy via the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway. Cisplatin 91-95 mechanistic target of rapamycin kinase Homo sapiens 188-217 32323781-6 2020 The aim of the present study was therefore to investigate whether miR-22 could mediate the CDDP resistance of OS cells by inhibiting autophagy via the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway. Cisplatin 91-95 mechanistic target of rapamycin kinase Homo sapiens 219-223 31558183-0 2020 Overexpression of the Long Noncoding RNA FOXD2-AS1 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma Through the miR-195/Akt/mTOR Axis. Cisplatin 60-69 mechanistic target of rapamycin kinase Homo sapiens 143-147 31843707-8 2020 Our results also indicated that cisplatin induced autophagy through the endoplasmic reticulum (ER) stress-mediated ATF4-Akt-mTOR signaling pathway. Cisplatin 32-41 mechanistic target of rapamycin kinase Homo sapiens 124-128 31558183-4 2020 In an in vitro assay, knockdown of FOXD2-AS1 noticeably inhibited cell invasion and growth, triggered cell death, and repressed the stimulation of the Akt/mTOR axis in cisplatin-resistant ESCC cells (TE-1/DDP). Cisplatin 168-177 mechanistic target of rapamycin kinase Homo sapiens 155-159 31558183-7 2020 FOXD2-AS1/miR-195/Akt/mTOR axis plays a crucial role in resistance to cisplatin in ESCC cells, offering an innovative strategy to treat ESCC. Cisplatin 70-79 mechanistic target of rapamycin kinase Homo sapiens 22-26 31267531-0 2020 microRNA-10b confers cisplatin resistance by activating AKT/mTOR/P70S6K signaling via targeting PPARgamma in esophageal cancer. Cisplatin 21-30 mechanistic target of rapamycin kinase Homo sapiens 60-64 31267531-10 2020 Inactivation of AKT/mTOR/p70S6K by AKT inhibitor (GSK690693) attenuated miR-10b-induced DDP resistance in esophageal cancer cells. Cisplatin 88-91 mechanistic target of rapamycin kinase Homo sapiens 20-24 31148231-0 2019 p53 induces miR-199a-3p to suppress mechanistic target of rapamycin activation in cisplatin-induced acute kidney injury. Cisplatin 82-91 mechanistic target of rapamycin kinase Homo sapiens 36-67 32277616-0 2020 Tormentic acid induces anticancer effects in cisplatin-resistant human cervical cancer cells mediated via cell cycle arrest, ROS production, and targeting mTOR/PI3K/AKT signalling pathway. Cisplatin 45-54 mechanistic target of rapamycin kinase Homo sapiens 155-159 32277616-16 2020 CONCLUSIONS: The outcomes of the present investigation suggest that tormentic acid-induced apoptotic effects in cisplatin-resistant HeLa cells were mediated via cell cycle arrest, ROS production and targeting of mTOR/PI3K/AKT signalling pathway. Cisplatin 112-121 mechanistic target of rapamycin kinase Homo sapiens 212-216 31411791-15 2019 CONCLUSION: Our data indicate that miR-1271 can inhibit the ovarian cancer epithelial-mesenchymal transition (EMT) and sensitize resistant cells to cisplatin-induced apoptosis through blocking mTOR expression. Cisplatin 148-157 mechanistic target of rapamycin kinase Homo sapiens 193-197 31703757-0 2019 Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition. Cisplatin 54-63 mechanistic target of rapamycin kinase Homo sapiens 115-119 32104214-4 2020 Furthermore, ghrelin activated the phosphoinositide 3-kinases/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway after cisplatin treatment. Cisplatin 136-145 mechanistic target of rapamycin kinase Homo sapiens 66-95 32104214-4 2020 Furthermore, ghrelin activated the phosphoinositide 3-kinases/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway after cisplatin treatment. Cisplatin 136-145 mechanistic target of rapamycin kinase Homo sapiens 106-110 31878245-11 2019 In vivo, treatment with OV alone or in combination with CDDP significantly reduced the tumor sphere-forming ability and decreased EV cargos containing mTOR, PI3K, STAT3, beta-catenin, and miR-21-5p. Cisplatin 56-60 mechanistic target of rapamycin kinase Homo sapiens 151-155 31729456-0 2019 Aspirin enhances cisplatin sensitivity of resistant non-small cell lung carcinoma stem-like cells by targeting mTOR-Akt axis to repress migration. Cisplatin 17-26 mechanistic target of rapamycin kinase Homo sapiens 111-115 31612051-0 2019 Polyphyllin I and VII potentiate the chemosensitivity of A549/DDP cells to cisplatin by enhancing apoptosis, reversing EMT and suppressing the CIP2A/AKT/mTOR signaling axis. Cisplatin 75-84 mechanistic target of rapamycin kinase Homo sapiens 153-157 31608140-5 2019 We found cell proliferation and survival signaling pathways AKT2/mTOR and MAPK were enhanced in cisplatin (CDDP)- and radiation-resistant neuroblastoma cells. Cisplatin 96-105 mechanistic target of rapamycin kinase Homo sapiens 65-69 31516578-7 2019 Luciferase reporter and western blotting assays demonstrated that transfection of the miR-101 mimic markedly reduced activity of the DNA-dependent protein kinase catalytic subunit/protein kinase B/mammalian target of rapamycin (DNA-PKcs/Akt/mTOR) pathway and increased expression of apoptotic protein caspase 3, which is induced by CDDP treatment. Cisplatin 332-336 mechanistic target of rapamycin kinase Homo sapiens 197-226 31516578-7 2019 Luciferase reporter and western blotting assays demonstrated that transfection of the miR-101 mimic markedly reduced activity of the DNA-dependent protein kinase catalytic subunit/protein kinase B/mammalian target of rapamycin (DNA-PKcs/Akt/mTOR) pathway and increased expression of apoptotic protein caspase 3, which is induced by CDDP treatment. Cisplatin 332-336 mechanistic target of rapamycin kinase Homo sapiens 241-245 31608140-5 2019 We found cell proliferation and survival signaling pathways AKT2/mTOR and MAPK were enhanced in cisplatin (CDDP)- and radiation-resistant neuroblastoma cells. Cisplatin 107-111 mechanistic target of rapamycin kinase Homo sapiens 65-69 31094028-7 2019 G-Rb3 diminished cisplatin-induced increase in protein expression levels of p62, Atg3, Atg5 and Atg7, and decrease in protein expression level of p-mTOR and the ratio of LC3-I/LC3-II, indicating that G-Rb3 suppressed cisplatin-induced activation of autophagy. Cisplatin 17-26 mechanistic target of rapamycin kinase Homo sapiens 148-152 31786876-11 2019 Furthermore, it was observed that Acetylshikonin could inhibit the mTOR/PI3K/AKT signalling pathway in the cisplatin-resistant KB-R oral cancer cells. Cisplatin 107-116 mechanistic target of rapamycin kinase Homo sapiens 67-71 31387554-11 2019 Furthermore, we observed that combination treatment with RAME and cisplatin greatly enhanced the anti-tumor effect in cisplatin-resistant cervical cancer cells, which was likely due to mTOR/S6K1 inhibition-mediated autophagy and apoptosis. Cisplatin 66-75 mechanistic target of rapamycin kinase Homo sapiens 185-189 31387554-11 2019 Furthermore, we observed that combination treatment with RAME and cisplatin greatly enhanced the anti-tumor effect in cisplatin-resistant cervical cancer cells, which was likely due to mTOR/S6K1 inhibition-mediated autophagy and apoptosis. Cisplatin 118-127 mechanistic target of rapamycin kinase Homo sapiens 185-189 31094028-10 2019 CONCLUSIONS: These findings clearly suggested that G-Rb3-mediated alleviation of cisplatin-induced nephrotoxicity was in part due to regulation of AMPK-/mTOR-mediated autophagy and inhibition of apoptosis in vitro and in vivo. Cisplatin 81-90 mechanistic target of rapamycin kinase Homo sapiens 153-157 31079851-12 2019 Importantly, apatinib enhanced anti-tumor effect of cisplatin on MDA-MB-231 cells via inhibiting the levels of p-VEGFR2, p-Akt and p-mTOR. Cisplatin 52-61 mechanistic target of rapamycin kinase Homo sapiens 133-137 31094028-0 2019 Ginsenoside Rb3 provides protective effects against cisplatin-induced nephrotoxicity via regulation of AMPK-/mTOR-mediated autophagy and inhibition of apoptosis in vitro and in vivo. Cisplatin 52-61 mechanistic target of rapamycin kinase Homo sapiens 109-113 31320816-9 2019 Furthermore, cisplatin-induced inactivation of mammalian target of rapamycin (mTOR) and histopathological damages were reversed by squalene. Cisplatin 13-22 mechanistic target of rapamycin kinase Homo sapiens 47-76 31234823-11 2019 Furthermore, the combination approach effectively inhibited PI3K/Akt/mTOR signaling pathway, reversed EMT, and decreased CSC marker expression in chemoresistant EOC cells compared with cisplatin mono-treatment. Cisplatin 185-194 mechanistic target of rapamycin kinase Homo sapiens 69-73 31234823-12 2019 CONCLUSIONS: Our results first demonstrate that EMT and enhanced CSC marker expression triggered by activated PI3K/Akt/mTOR signaling are involved in the chemoresistance of EOC, and BEZ235 in combination with cisplatin might be a promising treatment option to reverse EOC chemoresistance. Cisplatin 209-218 mechanistic target of rapamycin kinase Homo sapiens 119-123 31320816-9 2019 Furthermore, cisplatin-induced inactivation of mammalian target of rapamycin (mTOR) and histopathological damages were reversed by squalene. Cisplatin 13-22 mechanistic target of rapamycin kinase Homo sapiens 78-82 31081049-0 2019 Icariin enhances the chemosensitivity of cisplatin-resistant ovarian cancer cells by suppressing autophagy via activation of the AKT/mTOR/ATG5 pathway. Cisplatin 41-50 mechanistic target of rapamycin kinase Homo sapiens 133-137 30548308-8 2019 Moreover, downregulation of miR-340-5p partly reversed the inhibitory effect of OIP5-AS1 knockdown on the PI3K/AKT/mTOR pathway and therefore counteracted cisplatin resistance in MG63-CR and SaOS2-CR cells. Cisplatin 155-164 mechanistic target of rapamycin kinase Homo sapiens 115-119 30548308-0 2019 Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATbeta/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p. Cisplatin 35-44 mechanistic target of rapamycin kinase Homo sapiens 112-116 31033054-0 2019 Inhibition of PI3K/mTOR increased the sensitivity of hepatocellular carcinoma cells to cisplatin via interference with mitochondrial-lysosomal crosstalk. Cisplatin 87-96 mechanistic target of rapamycin kinase Homo sapiens 19-23 31033054-8 2019 Furthermore, a combination of cisplatin with the phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor PKI-402 induced lysosomal membrane permeabilization. Cisplatin 30-39 mechanistic target of rapamycin kinase Homo sapiens 115-119 31033054-10 2019 CONCLUSIONS: This is the first evidence of the importance of mitochondrial-lysosomal crosstalk in the cisplatin resistance of HCC cells and of the destruction of this crosstalk by a PI3K/mTOR inhibitor to increase the sensitivity of HCC cells to cisplatin. Cisplatin 102-111 mechanistic target of rapamycin kinase Homo sapiens 187-191 31033054-10 2019 CONCLUSIONS: This is the first evidence of the importance of mitochondrial-lysosomal crosstalk in the cisplatin resistance of HCC cells and of the destruction of this crosstalk by a PI3K/mTOR inhibitor to increase the sensitivity of HCC cells to cisplatin. Cisplatin 246-255 mechanistic target of rapamycin kinase Homo sapiens 187-191 30317677-0 2019 Long noncoding RNA growth arrest-specific 5 facilitates glioma cell sensitivity to cisplatin by suppressing excessive autophagy in an mTOR-dependent manner. Cisplatin 83-92 mechanistic target of rapamycin kinase Homo sapiens 134-138 30614075-8 2019 In addition, the core fucosylation could regulate the phosphorylation of cDDP-resistance-associated molecules, such as AKT, ERK, JNK, and mTOR. Cisplatin 73-77 mechanistic target of rapamycin kinase Homo sapiens 138-142 30317677-9 2019 In addition, GAS5 restored cisplatin-inhibited mammalian target of rapamycin (mTOR) activation. Cisplatin 27-36 mechanistic target of rapamycin kinase Homo sapiens 47-76 30317677-9 2019 In addition, GAS5 restored cisplatin-inhibited mammalian target of rapamycin (mTOR) activation. Cisplatin 27-36 mechanistic target of rapamycin kinase Homo sapiens 78-82 30317677-10 2019 Preconditioning with mTOR antagonist rapamycin engendered not only mTOR inhibition but also abrogated GAS5-mediated depression in cisplatin-evoked autophagy. Cisplatin 130-139 mechanistic target of rapamycin kinase Homo sapiens 21-25 30317677-11 2019 Notably, blocking the mTOR pathway also attenuated GAS5-increased sensitivity to cisplatin in U138 cells. Cisplatin 81-90 mechanistic target of rapamycin kinase Homo sapiens 22-26 30144378-9 2019 P53 silencing resulted in a very large decrement of cell death induced by ADP or by cisplatin and reverted ADP effects on mTOR/S6K phosphorylation, suggesting that activated p53 may act as a negative regulator of mTOR. Cisplatin 84-93 mechanistic target of rapamycin kinase Homo sapiens 122-126 30144378-9 2019 P53 silencing resulted in a very large decrement of cell death induced by ADP or by cisplatin and reverted ADP effects on mTOR/S6K phosphorylation, suggesting that activated p53 may act as a negative regulator of mTOR. Cisplatin 84-93 mechanistic target of rapamycin kinase Homo sapiens 213-217 30144378-10 2019 Consistently, the inhibition of mTOR by rapamycin also sensitized cells to cisplatin, and the effects of cisplatin plus rapamycin were identical to those obtained with cisplatin plus ADP. Cisplatin 75-84 mechanistic target of rapamycin kinase Homo sapiens 32-36 31128031-0 2019 A study on the mechanism of rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through PI3K/AKT/mTOR signaling pathway. Cisplatin 94-103 mechanistic target of rapamycin kinase Homo sapiens 121-125 31128031-1 2019 PURPOSE: To study the mechanism of rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through phosphatidylinositol 3-kinase (PI3K)/serine-threonine kinase (AKT)/mammalian target of rapamycin (mTOR) signaling pathway in vitro. Cisplatin 101-110 mechanistic target of rapamycin kinase Homo sapiens 186-215 31128031-1 2019 PURPOSE: To study the mechanism of rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through phosphatidylinositol 3-kinase (PI3K)/serine-threonine kinase (AKT)/mammalian target of rapamycin (mTOR) signaling pathway in vitro. Cisplatin 101-110 mechanistic target of rapamycin kinase Homo sapiens 217-221 31128031-7 2019 3: Rapamycin combined with cisplatin could inhibit the expressions of PI3K, AKT and phosphorylated mTOR (p-mTOR) in pancreatic cancer cells (p<0.05). Cisplatin 27-36 mechanistic target of rapamycin kinase Homo sapiens 99-103 31128031-7 2019 3: Rapamycin combined with cisplatin could inhibit the expressions of PI3K, AKT and phosphorylated mTOR (p-mTOR) in pancreatic cancer cells (p<0.05). Cisplatin 27-36 mechanistic target of rapamycin kinase Homo sapiens 107-111 31128031-8 2019 CONCLUSION: Rapamycin combined with cisplatin can alter the PI3K/AKT/mTOR signal transduction pathway which leads to markedly increased cell apoptosis rate, indicating that rapamycin can mediate the sensitivity of pancreatic cancer cells to cisplatin. Cisplatin 36-45 mechanistic target of rapamycin kinase Homo sapiens 69-73 31128031-8 2019 CONCLUSION: Rapamycin combined with cisplatin can alter the PI3K/AKT/mTOR signal transduction pathway which leads to markedly increased cell apoptosis rate, indicating that rapamycin can mediate the sensitivity of pancreatic cancer cells to cisplatin. Cisplatin 241-250 mechanistic target of rapamycin kinase Homo sapiens 69-73 31405336-0 2019 Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting PI3K/AKT/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer Cells. Cisplatin 30-39 mechanistic target of rapamycin kinase Homo sapiens 79-83 30528773-2 2019 A previous study showed that Met enhanced cytotoxic activity of cisplatin (Cis) in cholangiocarcinoma (CCA) in association with the activation of AMP-activated protein kinase and suppression of Akt-mTOR. Cisplatin 64-73 mechanistic target of rapamycin kinase Homo sapiens 198-202 30628719-0 2019 XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells. Cisplatin 23-32 mechanistic target of rapamycin kinase Homo sapiens 56-60 30066933-1 2018 The activation of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling and upregulation of excision repair cross complementation group 1 (ERCC1) are the two most important factors that confer resistance to cisplatin (DDP) therapy in non-small-cell lung cancer (NSCLC). Cisplatin 260-269 mechanistic target of rapamycin kinase Homo sapiens 78-107 30374107-7 2018 Additionally, maltol restored the reduction of PI3K/Akt and mTOR levels by cisplatin through increasing AMPK expression in cisplatin-treated HEK293 cells. Cisplatin 75-84 mechanistic target of rapamycin kinase Homo sapiens 60-64 30402851-0 2018 Regulation of mTOR by miR-107 to facilitate glioma cell apoptosis and to enhance cisplatin sensitivity. Cisplatin 81-90 mechanistic target of rapamycin kinase Homo sapiens 14-18 31405336-9 2019 The results indicated that inhibition of CD133 enhanced the Cis-KATO-III cell sensitivity to cisplatin by regulating PI3K/AKT/mTOR signaling pathway. Cisplatin 93-102 mechanistic target of rapamycin kinase Homo sapiens 126-130 31405336-10 2019 In summary, our data provide new insight that CD133 activates the PI3K/AKT/mTOR signaling transduction pathway, resulting in activation of autophagy and cisplatin resistance of Cis-KATO-III cells. Cisplatin 153-162 mechanistic target of rapamycin kinase Homo sapiens 75-79 30129654-4 2018 KIAA0101 activated the PI3K/AKT/mTOR signaling pathway to inhibit cisplatin-induced apoptosis and autophagy in ovarian cancer cells resulting in cisplatin resistance. Cisplatin 66-75 mechanistic target of rapamycin kinase Homo sapiens 32-36 30129654-4 2018 KIAA0101 activated the PI3K/AKT/mTOR signaling pathway to inhibit cisplatin-induced apoptosis and autophagy in ovarian cancer cells resulting in cisplatin resistance. Cisplatin 145-154 mechanistic target of rapamycin kinase Homo sapiens 32-36 29959912-0 2018 SAHA and cisplatin sensitize gastric cancer cells to doxorubicin by induction of DNA damage, apoptosis and perturbation of AMPK-mTOR signalling. Cisplatin 9-18 mechanistic target of rapamycin kinase Homo sapiens 128-132 29847773-0 2018 Metformin enhances cisplatin induced inhibition of cholangiocarcinoma cells via AMPK-mTOR pathway. Cisplatin 19-28 mechanistic target of rapamycin kinase Homo sapiens 85-89 30111296-11 2018 This cytotoxic effect was profound upon incorporation of metformin, an indirect mTOR inhibitor, in cisplatin nano-cubosomes. Cisplatin 99-108 mechanistic target of rapamycin kinase Homo sapiens 80-84 30280766-0 2018 MiR-100 up-regulation enhanced cell autophagy and apoptosis induced by cisplatin in osteosarcoma by targeting mTOR. Cisplatin 71-80 mechanistic target of rapamycin kinase Homo sapiens 110-114 30280766-16 2018 MiR-100 up-regulation enhanced cell autophagy and apoptosis induced by cisplatin via targeted inhibiting of mTOR. Cisplatin 71-80 mechanistic target of rapamycin kinase Homo sapiens 108-112 29535821-3 2018 In this study, we hypothesized that NVP-BEZ235, a dual inhibitor of PI3K/mTOR, could synergize cisplatin sensitivity in OS. Cisplatin 95-104 mechanistic target of rapamycin kinase Homo sapiens 73-77 29808802-11 2018 Furthermore, the PI3K-AKT-mTOR pathway activation could be inhibited by cisplatin in BM-MSCs, while flavored Guilu Erxian decoction treatment successfully abrogated this effect. Cisplatin 72-81 mechanistic target of rapamycin kinase Homo sapiens 26-30 31938149-8 2018 In addition, knockdown of Sall4 significantly inhibited cell proliferation, induced apoptosis and invasion cisplatin-resistant A549 cells through AKT/mTOR signaling. Cisplatin 107-116 mechanistic target of rapamycin kinase Homo sapiens 150-154 29736216-7 2018 We also found that in our cisplatin-resistant cells, knockdown of Rab5a activated autophagy via mTOR pathway and could reverse drug resistance while overexpression of Rab5a in drug sensitive cells increased drug tolerance. Cisplatin 26-35 mechanistic target of rapamycin kinase Homo sapiens 96-100 29456744-2 2018 mTOR activation decreases the sensitivity of ovarian cancer to cisplatin. Cisplatin 63-72 mechanistic target of rapamycin kinase Homo sapiens 0-4 29456744-10 2018 These results demonstrated that the combinatorial effects of cardamonin and cisplatin on anti-proliferation were enhanced by suppressing the expression of anti-apoptotic proteins and activation of mTOR in ovarian cancer cells. Cisplatin 76-85 mechanistic target of rapamycin kinase Homo sapiens 197-201 29535821-5 2018 Cisplatin could activate PI3K-Akt-mTOR pathway activity in early times, whereas, NVP-BEZ235 could inhibit PI3K-Akt -mTOR pathway activity all the times alone or combined with cisplatin. Cisplatin 0-9 mechanistic target of rapamycin kinase Homo sapiens 34-38 28693382-0 2017 miR-7 Increases Cisplatin Sensitivity of Gastric Cancer Cells Through Suppressing mTOR. Cisplatin 16-25 mechanistic target of rapamycin kinase Homo sapiens 82-86 28693382-7 2017 More interestingly, microRNA-7 also sensitizes gastric cancer cells to cisplatin (CDDP) by targeting mTOR. Cisplatin 71-80 mechanistic target of rapamycin kinase Homo sapiens 101-105 28693382-7 2017 More interestingly, microRNA-7 also sensitizes gastric cancer cells to cisplatin (CDDP) by targeting mTOR. Cisplatin 82-86 mechanistic target of rapamycin kinase Homo sapiens 101-105 29033791-8 2017 Similar to what was found after gentamicin exposure, cisplatin activates both the c-Jun N-terminal kinase (JNK) and mammalian target of rapamycin (mTOR) pathways. Cisplatin 53-62 mechanistic target of rapamycin kinase Homo sapiens 116-145 29100507-0 2017 Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38. Cisplatin 38-47 mechanistic target of rapamycin kinase Homo sapiens 23-27 29100507-10 2017 However, the dual phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor NVP-BEZ235 acted synergistically with cisplatin in HCC38CisR and fully restored cisplatin sensitivity. Cisplatin 140-149 mechanistic target of rapamycin kinase Homo sapiens 86-90 29033791-8 2017 Similar to what was found after gentamicin exposure, cisplatin activates both the c-Jun N-terminal kinase (JNK) and mammalian target of rapamycin (mTOR) pathways. Cisplatin 53-62 mechanistic target of rapamycin kinase Homo sapiens 147-151 29156674-6 2017 The addition of PI3K-mTOR inhibitors to cisplatin or paclitaxel increased the activity of chemotherapy in the TNBC and LGSOC models; whereas no added activity was observed in the LADC model. Cisplatin 40-49 mechanistic target of rapamycin kinase Homo sapiens 21-25 28939129-0 2017 Salvianolic acid A reverses cisplatin resistance in lung cancer A549 cells by targeting c-met and attenuating Akt/mTOR pathway. Cisplatin 28-37 mechanistic target of rapamycin kinase Homo sapiens 114-118 28939129-5 2017 Moreover, we revealed that SAA enhanced sensitivity to cisplatin in A549/DDP cells mainly through suppression of the c-met/AKT/mTOR signaling pathway. Cisplatin 55-64 mechanistic target of rapamycin kinase Homo sapiens 127-131 28737828-0 2017 TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma. Cisplatin 39-48 mechanistic target of rapamycin kinase Homo sapiens 57-61 28737828-9 2017 When the AKT/mTOR pathway was blocked in A549 and H460 with TAZ overexpression, cisplatin sensitivity was assessed by IC50 value. Cisplatin 80-89 mechanistic target of rapamycin kinase Homo sapiens 13-17 28737828-14 2017 Furthermore, we found that the inhibition of the AKT/mTOR pathway rescued the cells from cisplatin resistance caused by TAZ overexpression. Cisplatin 89-98 mechanistic target of rapamycin kinase Homo sapiens 53-57 28737828-15 2017 Our data revealed that TAZ inhibition restores sensitivity of cisplatin in lung adenocarcinoma, which was, at least in part, AKT/mTOR signaling pathway-dependent. Cisplatin 62-71 mechanistic target of rapamycin kinase Homo sapiens 129-133 28979680-12 2017 Meanwhile, cisplatin activated the AKT-mTOR pathway in both SKOV3 and hey cells. Cisplatin 11-20 mechanistic target of rapamycin kinase Homo sapiens 39-43 28979680-16 2017 CONCLUSION: Based on our study, we propose that cisplatin activates the AKT/mTOR signaling pathway, which subsequently induces cytoprotective autophagy in ovarian cancer cells. Cisplatin 48-57 mechanistic target of rapamycin kinase Homo sapiens 76-80 28197628-0 2017 Resveratrol-induced autophagy and apoptosis in cisplatin-resistant human oral cancer CAR cells: A key role of AMPK and Akt/mTOR signaling. Cisplatin 47-56 mechanistic target of rapamycin kinase Homo sapiens 123-127 27799485-4 2017 Cisplatin also induced the phosphorylation of mammalian target of rapamycin (mTOR), p70S6 kinase downstream of mTOR, and serine/threonine-protein kinase ULK1, a component of the autophagy initiating complex. Cisplatin 0-9 mechanistic target of rapamycin kinase Homo sapiens 46-75 27799485-4 2017 Cisplatin also induced the phosphorylation of mammalian target of rapamycin (mTOR), p70S6 kinase downstream of mTOR, and serine/threonine-protein kinase ULK1, a component of the autophagy initiating complex. Cisplatin 0-9 mechanistic target of rapamycin kinase Homo sapiens 77-81 27799485-4 2017 Cisplatin also induced the phosphorylation of mammalian target of rapamycin (mTOR), p70S6 kinase downstream of mTOR, and serine/threonine-protein kinase ULK1, a component of the autophagy initiating complex. Cisplatin 0-9 mechanistic target of rapamycin kinase Homo sapiens 111-115 28161641-0 2017 Neferine reduces cisplatin-induced nephrotoxicity by enhancing autophagy via the AMPK/mTOR signaling pathway. Cisplatin 17-26 mechanistic target of rapamycin kinase Homo sapiens 86-90 28422725-6 2017 Rescue experiments proved that miR-199a-3p could increase the cisplatin sensitivity of cholangiocarcinoma cell lines by regulating mTOR expression. Cisplatin 62-71 mechanistic target of rapamycin kinase Homo sapiens 131-135 28422725-8 2017 In conclusion, miR-199a-3p could increase cisplatin sensitivity of cholangiocarcinoma cell lines by inhibiting the activity of the mTOR signaling pathway and decreasing the expression of MDR1. Cisplatin 42-51 mechanistic target of rapamycin kinase Homo sapiens 131-135 28223119-4 2017 Co-treatment with neferine enhanced cisplatin-induced autophagy in A549 cells was accompanied by Acidic vesicular accumulation (AVO), enhanced generation of reactive oxygen species (ROS) and depletion of intracellular glutathione (GSH), down regulation of PI3K/AKT/mTOR pathway, conversion of LC3B-I to LC3B-II. Cisplatin 36-45 mechanistic target of rapamycin kinase Homo sapiens 265-269 28223119-6 2017 In conclusion, these results suggest that neferine enhances cisplatin -induced autophagic cancer cell death through downregulation of PI3K/Akt/mTOR signaling pro-survival pathway and ROS- mediated Beclin-1 and PI3K CIII independent autophagy in human lung adenocarcinoma (A549 cells). Cisplatin 60-69 mechanistic target of rapamycin kinase Homo sapiens 143-147 28521459-0 2017 Cisplatin regulates cell autophagy in endometrial cancer cells via the PI3K/AKT/mTOR signalling pathway. Cisplatin 0-9 mechanistic target of rapamycin kinase Homo sapiens 80-84 28521459-11 2017 The results indicated that CDDP treatment inactivated the PI3K/AKT/mTOR signalling pathway. Cisplatin 27-31 mechanistic target of rapamycin kinase Homo sapiens 67-71 28521459-14 2017 In brief, the present study hypothesized that CDDP may regulate cell autophagy in the Ishikawa endometrial cancer cell line via the PI3K/AKT/mTOR signalling pathway. Cisplatin 46-50 mechanistic target of rapamycin kinase Homo sapiens 141-145 28459375-0 2017 Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway. Cisplatin 88-97 mechanistic target of rapamycin kinase Homo sapiens 132-136 28459375-1 2017 This study aimed to investigate the effects of long non-coding RNA ROR (regulator of reprogramming) on cisplatin (DDP) resistance in patients with non-small-cell lung cancer by regulating PI3K/Akt/mTOR signaling pathway. Cisplatin 103-112 mechanistic target of rapamycin kinase Homo sapiens 197-201 27433879-12 2017 Cisplatin treatment inhibited the phosphorylation of mTOR/P70S6K, and its phosphorylated strips were almost completely inhibited in the 100 mumol/L for 48 hours with cisplatin treatment. Cisplatin 0-9 mechanistic target of rapamycin kinase Homo sapiens 53-57 27433879-12 2017 Cisplatin treatment inhibited the phosphorylation of mTOR/P70S6K, and its phosphorylated strips were almost completely inhibited in the 100 mumol/L for 48 hours with cisplatin treatment. Cisplatin 166-175 mechanistic target of rapamycin kinase Homo sapiens 53-57 27492148-0 2016 PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer. Cisplatin 34-43 mechanistic target of rapamycin kinase Homo sapiens 73-77 28035350-5 2017 Exogenous LPAATbeta mediated by heritable RNAi decreased cisplatin-resistant sensitivity through activating the PI3K/Akt/mTOR signaling pathway. Cisplatin 57-66 mechanistic target of rapamycin kinase Homo sapiens 121-125 27639426-0 2016 Inhibition of autophagy by andrographolide resensitizes cisplatin-resistant non-small cell lung carcinoma cells via activation of the Akt/mTOR pathway. Cisplatin 56-65 mechanistic target of rapamycin kinase Homo sapiens 138-142 27639426-6 2016 Andrographolide, a natural diterpenoid, promoted the activation of the Akt/mTOR signaling by downregulating PTEN and suppressed autophagy, which subsequently resensitized the resistant cells to cisplatin-mediated apoptosis. Cisplatin 194-203 mechanistic target of rapamycin kinase Homo sapiens 75-79 27639426-8 2016 These results highlight the involvement of autophagy in cisplatin-resistance development and suggest that inhibition of autophagy via tuning the Akt/mTOR signaling could be a promising strategy in the therapy for cisplatin-resistant non-small cell lung cancer. Cisplatin 213-222 mechanistic target of rapamycin kinase Homo sapiens 149-153 27840166-8 2016 The synergistic effect of polymet alongside CDDP demonstrates that polymet-CDDP NPs can activate the AMP-activated protein kinase alpha (AMPKalpha) pathway and inhibit mammalian target rapamycin (mTOR) activity to enhance growth suppression. Cisplatin 44-48 mechanistic target of rapamycin kinase Homo sapiens 196-200 27045863-0 2016 Huaier aqueous extract sensitizes cells to rapamycin and cisplatin through activating mTOR signaling. Cisplatin 57-66 mechanistic target of rapamycin kinase Homo sapiens 86-90 27104982-0 2016 TDRG1 regulates chemosensitivity of seminoma TCam-2 cells to cisplatin via PI3K/Akt/mTOR signaling pathway and mitochondria-mediated apoptotic pathway. Cisplatin 61-70 mechanistic target of rapamycin kinase Homo sapiens 84-88 27104982-5 2016 Mechanistically, we observed TDRG1 positively regulated the expression levels of the key elements in PI3K/Akt/mTOR pathway including p-PI3K, p-Akt and p-mTOR and also affected the translocation of nuclear p-Akt in TCam-2 cells during cisplatin treatment. Cisplatin 234-243 mechanistic target of rapamycin kinase Homo sapiens 110-114 27104982-10 2016 In conclusion, we uncover that TDRG1 regulates chemosensitivity of TCam-2 cells to cisplatin through PI3K/Akt/mTOR signaling and mitochondria-mediated apoptotic pathway both in vitro and in vivo. Cisplatin 83-92 mechanistic target of rapamycin kinase Homo sapiens 110-114 27261591-6 2016 Finally, we demonstrated that cisplatin induced protective autophagy which was involved of PI3K/Akt/mTOR pathway. Cisplatin 30-39 mechanistic target of rapamycin kinase Homo sapiens 100-104 27492148-7 2016 High levels of mTOR, HIF-1alpha, c-Myc, and PKM2 were associated with a positive chemotherapy response in cervical cancer patients treated with cisplatin-based NACT. Cisplatin 144-153 mechanistic target of rapamycin kinase Homo sapiens 15-19 27014910-10 2016 In addition, we revealed that miR-206 overexpression reduced cisplatin resistance and EMT in DDP-resistant cells, partly due to inactivation of MET/PI3K/AKT/mTOR signaling pathway, and subsequent downregulation of MDR1, ZEB1 and Snail expression. Cisplatin 61-70 mechanistic target of rapamycin kinase Homo sapiens 157-161 27492148-10 2016 mTOR, HIF1alpha, c-Myc, and PKM2 expression in cervical cancer may serve as predictive biomarkers to cisplatin-based chemotherapy. Cisplatin 101-110 mechanistic target of rapamycin kinase Homo sapiens 0-4 27492148-11 2016 PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer. Cisplatin 34-43 mechanistic target of rapamycin kinase Homo sapiens 73-77 26895469-9 2016 Our findings reveal a new mechanism by which EGFR/PI3K/Akt/mTOR signaling promotes head and neck cancer progression and underscores the need for developing a therapeutic strategy for targeting IKK/NF-kappaB either as a single agent or in combination with cisplatin in head and neck cancer. Cisplatin 255-264 mechanistic target of rapamycin kinase Homo sapiens 59-63 26526583-3 2016 In this study, we showed that rapamycin inhibited the mammalian target of rapamycin (mTOR) signal transduction in A549 cells and improved the sensitivity to cisplatin (DDP). Cisplatin 157-166 mechanistic target of rapamycin kinase Homo sapiens 54-83 27045863-9 2016 Moreover, activation of mTOR signaling induced by Huaier contributes to the increased sensitivity of cells to rapamycin or cisplatin in response to Huaier treatment. Cisplatin 123-132 mechanistic target of rapamycin kinase Homo sapiens 24-28 27090655-8 2016 Mechanism of action molecular model representations of cisplatin and paclitaxel embed the very same signaling components, and specifically proteins afflicted with the activation status of the mTOR pathway become evident, including VEGFA. Cisplatin 55-64 mechanistic target of rapamycin kinase Homo sapiens 192-196 27090655-9 2016 Analyzing mechanism of action interference of the mTOR inhibitor sirolimus shows specific impact on the drug resistance signature imposed by cisplatin and paclitaxel, further holding evidence for a synthetic lethal interaction to paclitaxel mechanism of action involving cyclin D1. Cisplatin 141-150 mechanistic target of rapamycin kinase Homo sapiens 50-54 25917382-0 2016 Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil. Cisplatin 176-185 mechanistic target of rapamycin kinase Homo sapiens 16-45 25917382-1 2016 BACKGROUND: This study evaluated the significance of mammalian target of rapamycin (mTOR) activation on the prognosis of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF). Cisplatin 247-256 mechanistic target of rapamycin kinase Homo sapiens 53-82 25917382-1 2016 BACKGROUND: This study evaluated the significance of mammalian target of rapamycin (mTOR) activation on the prognosis of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF). Cisplatin 247-256 mechanistic target of rapamycin kinase Homo sapiens 84-88 26526583-3 2016 In this study, we showed that rapamycin inhibited the mammalian target of rapamycin (mTOR) signal transduction in A549 cells and improved the sensitivity to cisplatin (DDP). Cisplatin 157-166 mechanistic target of rapamycin kinase Homo sapiens 85-89 27293459-0 2016 Guizhi Fuling Wan, a Traditional Chinese Herbal Formula, Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Inactivation of the PI3K/AKT/mTOR Pathway. Cisplatin 68-77 mechanistic target of rapamycin kinase Homo sapiens 152-156 26800397-0 2016 miR-222 attenuates cisplatin-induced cell death by targeting the PPP2R2A/Akt/mTOR Axis in bladder cancer cells. Cisplatin 19-28 mechanistic target of rapamycin kinase Homo sapiens 77-81 26800397-6 2016 Blocking the activation of Akt with LY294002 or mTOR with rapamycin significantly prevented miR-222-induced proliferation and restored the sensitivity of bladder cancer cells to cisplatin. Cisplatin 178-187 mechanistic target of rapamycin kinase Homo sapiens 48-52 27293459-6 2016 GFW could sensitize cisplatin-resistant SKOV3/DDP cells by inhibiting the protein level and function of P-gp, which may be medicated through inactivation of the PI3K/AKT/mTOR pathway. Cisplatin 20-29 mechanistic target of rapamycin kinase Homo sapiens 170-174 25450742-7 2015 Cisplatin affected several pathways including, p53 signalling, Nrf2 mediated oxidative stress response, mitochondrial processes, mTOR and AMPK signalling. Cisplatin 0-9 mechanistic target of rapamycin kinase Homo sapiens 129-133 26238185-0 2015 MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1. Cisplatin 18-27 mechanistic target of rapamycin kinase Homo sapiens 76-80 26715839-0 2015 Autophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK/mTOR signaling pathway. Cisplatin 56-65 mechanistic target of rapamycin kinase Homo sapiens 98-102 26715839-9 2015 Compared to cisplatin treatment alone, the combination of cisplatin and CQ decreased p-AMPK and increased p-mTOR protein expressions, in addition, the AMPK inhibitor Compound C plus cisplatin downregulated p-AMPK and upregulated p-mTOR as well as depressed LC3B cleavage. Cisplatin 58-67 mechanistic target of rapamycin kinase Homo sapiens 108-112 26715839-9 2015 Compared to cisplatin treatment alone, the combination of cisplatin and CQ decreased p-AMPK and increased p-mTOR protein expressions, in addition, the AMPK inhibitor Compound C plus cisplatin downregulated p-AMPK and upregulated p-mTOR as well as depressed LC3B cleavage. Cisplatin 58-67 mechanistic target of rapamycin kinase Homo sapiens 231-235 26715839-9 2015 Compared to cisplatin treatment alone, the combination of cisplatin and CQ decreased p-AMPK and increased p-mTOR protein expressions, in addition, the AMPK inhibitor Compound C plus cisplatin downregulated p-AMPK and upregulated p-mTOR as well as depressed LC3B cleavage. Cisplatin 58-67 mechanistic target of rapamycin kinase Homo sapiens 108-112 26715839-9 2015 Compared to cisplatin treatment alone, the combination of cisplatin and CQ decreased p-AMPK and increased p-mTOR protein expressions, in addition, the AMPK inhibitor Compound C plus cisplatin downregulated p-AMPK and upregulated p-mTOR as well as depressed LC3B cleavage. Cisplatin 58-67 mechanistic target of rapamycin kinase Homo sapiens 231-235 26715839-10 2015 These findings demonstrate that activation of autophagy is a hallmark of cisplatin exposure in human lung adenocarcinoma cells, and that there is a cisplatin-induced autophagic response via activation of the AMPK/mTOR signaling pathway. Cisplatin 148-157 mechanistic target of rapamycin kinase Homo sapiens 213-217 26505347-7 2015 Interestingly, in the kidney, cisplatin treatment can activate AMP-activated protein kinase (AMPK), a signaling molecule that is also critical for p53-mediated inactivation of mammalian target of rapamycin (mTOR) pathways. Cisplatin 30-39 mechanistic target of rapamycin kinase Homo sapiens 176-205 26505347-7 2015 Interestingly, in the kidney, cisplatin treatment can activate AMP-activated protein kinase (AMPK), a signaling molecule that is also critical for p53-mediated inactivation of mammalian target of rapamycin (mTOR) pathways. Cisplatin 30-39 mechanistic target of rapamycin kinase Homo sapiens 207-211 26505347-10 2015 Given the fact that p53 can regulate autophagy by inactivating mTOR via AMPK, our results suggest that the p53 pathway may also play a critical role in the pathogenesis of cisplatin-induced renal damage. Cisplatin 172-181 mechanistic target of rapamycin kinase Homo sapiens 63-67 26023849-0 2015 Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer. Cisplatin 78-87 mechanistic target of rapamycin kinase Homo sapiens 18-22 26711828-0 2015 [Involvement of miR-199a in cisplatin resistance of ovarian cancer cell through modulating expression of mTOR]. Cisplatin 28-37 mechanistic target of rapamycin kinase Homo sapiens 105-109 26711828-6 2015 CONCLUSION: miR-199a regulates the sensitivity of ovarian cancer cells to cisplatin through modulating expression of mTOR, and involves in the cisplatin resistance process of ovarian cancer cells. Cisplatin 74-83 mechanistic target of rapamycin kinase Homo sapiens 117-121 26201060-0 2015 The role of mTOR during cisplatin treatment in an in vitro and ex vivo model of cervical cancer. Cisplatin 24-33 mechanistic target of rapamycin kinase Homo sapiens 12-16 26201060-3 2015 Resistance to cisplatin is often attributed to a disruption in the normal apoptotic response via aberrant activation of pathways such as the mTOR pathway. Cisplatin 14-23 mechanistic target of rapamycin kinase Homo sapiens 141-145 26201060-4 2015 Here we assess the role of mTOR and its effect on cell death sensitization and autophagy in response to a low concentration of cisplatin in cervical cancer cells. Cisplatin 127-136 mechanistic target of rapamycin kinase Homo sapiens 27-31 26201060-10 2015 Cisplatin cytotoxicity was greatly enhanced in cancer cells when mTOR had been inhibited prior to cisplatin treatment which was likely due to autophagy being increased above cisplatin-induced levels, thereby inducing apoptosis. Cisplatin 0-9 mechanistic target of rapamycin kinase Homo sapiens 65-69 26201060-10 2015 Cisplatin cytotoxicity was greatly enhanced in cancer cells when mTOR had been inhibited prior to cisplatin treatment which was likely due to autophagy being increased above cisplatin-induced levels, thereby inducing apoptosis. Cisplatin 174-183 mechanistic target of rapamycin kinase Homo sapiens 65-69 26201060-12 2015 Our data suggest that utilising a lower dose of cisplatin combined with mTOR inhibition is a viable treatment option and addresses the challenge of cisplatin dose-dependent toxicity, however future studies are required to confirm this in a clinical setting. Cisplatin 148-157 mechanistic target of rapamycin kinase Homo sapiens 72-76 25400422-0 2014 Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro. Cisplatin 116-125 mechanistic target of rapamycin kinase Homo sapiens 23-27 25890004-2 2015 The purpose of this study was to investigate the anti-tumoral effect of the mTOR inhibitor (mTORi) CCI-779 in HNSCC cell lines and its potency in cisplatin- and cetuximab-resistant cells. Cisplatin 146-155 mechanistic target of rapamycin kinase Homo sapiens 76-80 26278147-2 2015 Expressions of mTOR and its target molecules p70S6K and 4E-BP1 were determined in A2780cis and COC1/DDP and the parental cells A2780 and COC1 that are sensitive to cisplatin using Western blotting. Cisplatin 164-173 mechanistic target of rapamycin kinase Homo sapiens 15-19 25988128-8 2014 EGCG improved efficacy of cisplatin treatment in HeLa cells by regulating NFkappaB p65, COX-2, p-Akt, and p-mTOR pathways, whereas it increased the expression levels of Nrf2/HO-1 in combined therapy. Cisplatin 26-35 mechanistic target of rapamycin kinase Homo sapiens 108-112 25976336-2 2015 METHODS/MATERIALS: Expressions of mTOR and its target molecules p70S6K and 4E-BP1 were determined in cisplatin-sensitive and -resistant cells A2780 and A2780cis, respectively, using Western blotting. Cisplatin 101-110 mechanistic target of rapamycin kinase Homo sapiens 34-38 25976336-6 2015 The levels of phosphorylated mTOR (p-mTOR), p70S6K, and 4E-BP1 were significantly increased in A2780cis cells compared to A2780 cells, which might be implicated in cisplatin-induced chemoresistance. Cisplatin 164-173 mechanistic target of rapamycin kinase Homo sapiens 29-33 25976336-6 2015 The levels of phosphorylated mTOR (p-mTOR), p70S6K, and 4E-BP1 were significantly increased in A2780cis cells compared to A2780 cells, which might be implicated in cisplatin-induced chemoresistance. Cisplatin 164-173 mechanistic target of rapamycin kinase Homo sapiens 37-41 25400422-3 2014 The results showed that PI-103 could significantly increase the sensitivity of SKVO3/DDP cells to cisplatin through inhibiting the activation of PI3K/Akt/mTOR signaling pathway and inducing cell cycle arrest and apoptosis. Cisplatin 98-107 mechanistic target of rapamycin kinase Homo sapiens 154-158 24969552-0 2014 NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells. Cisplatin 92-101 mechanistic target of rapamycin kinase Homo sapiens 24-28 25109763-8 2014 In addition, the combination of FTY720 and cisplatin reduced the protein expression of SK1 and the phosphorylation levels of phosphoinositide 3-kinase (PI3K), Akt and mTOR in the SK-Mel-28 cells; the expression of epidermal growth factor receptor (EGFR) was also markedly reduced. Cisplatin 43-52 mechanistic target of rapamycin kinase Homo sapiens 167-171 25109763-9 2014 These findings suggest that FTY720 and cisplatin synergistically induce cell death through the downregulation of the PI3K/Akt/mTOR pathway and the decrease in EGFR expression in SK-Mel-28 cells. Cisplatin 39-48 mechanistic target of rapamycin kinase Homo sapiens 126-130 24969552-10 2014 The present study demonstrated that the PI3K/mTOR dual inhibitor NVP-BEZ235 can synergistically potentiate the antitumor effects of cisplatin in cisplatin-resistant bladder cancer cells though the suppression of cell cycle progression and the survival pathway as well as induction of caspase-dependent apoptosis. Cisplatin 132-141 mechanistic target of rapamycin kinase Homo sapiens 45-49 24969552-10 2014 The present study demonstrated that the PI3K/mTOR dual inhibitor NVP-BEZ235 can synergistically potentiate the antitumor effects of cisplatin in cisplatin-resistant bladder cancer cells though the suppression of cell cycle progression and the survival pathway as well as induction of caspase-dependent apoptosis. Cisplatin 145-154 mechanistic target of rapamycin kinase Homo sapiens 45-49 25642303-6 2014 The antagonistic effect of metformin on cisplatin could be through survivin and mTOR signaling pathways. Cisplatin 40-49 mechanistic target of rapamycin kinase Homo sapiens 80-84 25221647-0 2014 NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/mTOR pathway in cisplatin-resistant non-small cell lung carcinoma. Cisplatin 81-90 mechanistic target of rapamycin kinase Homo sapiens 65-69 25221647-2 2014 In this study, we hypothesized that the dual inhibitor of phosphatidylinositol-3 kinase/mammalian target of rapamycin, NVP-BEZ-235, could potentially enhance radiosensitization in cisplatin-resistance (CDDP-R) non-small cell lung cancer (NSCLC) cells by disabling autophagy as a mechanism of self-preservation. Cisplatin 180-189 mechanistic target of rapamycin kinase Homo sapiens 88-117 25221647-4 2014 RESULTS: Basal p-Akt, p-mTOR and p-S6R proteins were enhanced in CDDP-R NSCLC cells. Cisplatin 65-69 mechanistic target of rapamycin kinase Homo sapiens 24-28 24799992-0 2014 Melatonin attenuates cisplatin-induced HepG2 cell death via the regulation of mTOR and ERCC1 expressions. Cisplatin 21-30 mechanistic target of rapamycin kinase Homo sapiens 78-82 24462866-0 2014 Dihydroartemisinin potentiates the anticancer effect of cisplatin via mTOR inhibition in cisplatin-resistant ovarian cancer cells: involvement of apoptosis and autophagy. Cisplatin 56-65 mechanistic target of rapamycin kinase Homo sapiens 70-74 24462866-0 2014 Dihydroartemisinin potentiates the anticancer effect of cisplatin via mTOR inhibition in cisplatin-resistant ovarian cancer cells: involvement of apoptosis and autophagy. Cisplatin 89-98 mechanistic target of rapamycin kinase Homo sapiens 70-74 24462866-5 2014 Here, we show that compared with control ovarian cancer cells (SKOV3), mTOR phosphorylation was abnormally activated in cisplatin-resistant ovarian cancer cells (SKOV3/DDP) following cisplatin monotherapy. Cisplatin 120-129 mechanistic target of rapamycin kinase Homo sapiens 71-75 24462866-5 2014 Here, we show that compared with control ovarian cancer cells (SKOV3), mTOR phosphorylation was abnormally activated in cisplatin-resistant ovarian cancer cells (SKOV3/DDP) following cisplatin monotherapy. Cisplatin 183-192 mechanistic target of rapamycin kinase Homo sapiens 71-75 24462866-9 2014 Taken together, we conclude that inhibition of cisplatin-induced mTOR activation is one of the main mechanisms by which DHA dramatically promotes its anticancer effect in cisplatin-resistant ovarian cancer cells. Cisplatin 47-56 mechanistic target of rapamycin kinase Homo sapiens 65-69 24462866-9 2014 Taken together, we conclude that inhibition of cisplatin-induced mTOR activation is one of the main mechanisms by which DHA dramatically promotes its anticancer effect in cisplatin-resistant ovarian cancer cells. Cisplatin 171-180 mechanistic target of rapamycin kinase Homo sapiens 65-69 25642303-5 2014 When MKN-45 cells were treated with metformin/cisplatin, the expression of survivin and mTOR were increased. Cisplatin 46-55 mechanistic target of rapamycin kinase Homo sapiens 88-92 25030585-8 2014 The expressions of mTOR and Beclin1 mRNA were highest in the (Saquinavair+DDP) group, 0.684 +- 0.072 and 0.647 +- 0.047, respectively; Secondly, the Saquinavair group, 0.577 +- 0.016 and 0.565 +- 0.037, respectively. Cisplatin 74-77 mechanistic target of rapamycin kinase Homo sapiens 19-23 25030585-9 2014 The expressions of mTOR and Beclin1 proteins were also highest in the (Saquinavair+DDP) group, 0.624 +- 0.058 and 0.924 +- 0.033, respectively, followed by the Saquinavair group, 0.544 +- 0.019 and 0.712 +- 0.024. Cisplatin 83-86 mechanistic target of rapamycin kinase Homo sapiens 19-23 25030585-13 2014 The mechanism of the decrease of sensitivity to cisplatin in SKOV3 cells may be that ERS regulates cell autophagy through the mTOR and Beclin1 pathways. Cisplatin 48-57 mechanistic target of rapamycin kinase Homo sapiens 126-130 24799992-13 2014 In the combination treatment, melatonin reversed the effects of cisplatin by suppressing the over-expression of mTOR and ERCC 1 and enhancing the expression levels of Beclin-1 and microtubule-associated protein-light chain3-II, leading to intracellular autophagosome progression. Cisplatin 64-73 mechanistic target of rapamycin kinase Homo sapiens 112-116 24875127-0 2014 miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. Cisplatin 19-28 mechanistic target of rapamycin kinase Homo sapiens 101-105 24568519-0 2014 MicroRNA-100 resensitizes resistant chondrosarcoma cells to cisplatin through direct targeting of mTOR. Cisplatin 60-69 mechanistic target of rapamycin kinase Homo sapiens 98-102 24568519-6 2014 Overexpression of miR-100 complementary pairs to the 3" untranslated region (UTR) of mTOR, resulted in sensitization of cisplatin resistant cells to cisplatin. Cisplatin 120-129 mechanistic target of rapamycin kinase Homo sapiens 85-89 24568519-6 2014 Overexpression of miR-100 complementary pairs to the 3" untranslated region (UTR) of mTOR, resulted in sensitization of cisplatin resistant cells to cisplatin. Cisplatin 149-158 mechanistic target of rapamycin kinase Homo sapiens 85-89 24568519-7 2014 Moreover, recovery of the mTOR pathway by overexpression of S6K desensitized the chondrosarcoma cells to cisplatin, suggesting the miR-100-mediated sensitization to cisplatin dependent on inhibition of mTOR. Cisplatin 105-114 mechanistic target of rapamycin kinase Homo sapiens 26-30 24568519-7 2014 Moreover, recovery of the mTOR pathway by overexpression of S6K desensitized the chondrosarcoma cells to cisplatin, suggesting the miR-100-mediated sensitization to cisplatin dependent on inhibition of mTOR. Cisplatin 165-174 mechanistic target of rapamycin kinase Homo sapiens 26-30 24137412-0 2013 microRNA-199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mammalian target of rapamycin. Cisplatin 33-42 mechanistic target of rapamycin kinase Homo sapiens 110-139 24438628-15 2014 The activation of PI3K/Akt/mTOR signaling pathway induced by insulin resulted in the suppression of autophagy in EC9706 cells, which may be attributed to the anticancer effects of cisplatin. Cisplatin 180-189 mechanistic target of rapamycin kinase Homo sapiens 27-31 24818169-0 2014 Targeted inhibition of mTOR signaling improves sensitivity of esophageal squamous cell carcinoma cells to cisplatin. Cisplatin 106-115 mechanistic target of rapamycin kinase Homo sapiens 23-27 24818169-2 2014 The aims of this study were to investigate the expression of mTOR in ESCC tissues and its relationship with progression of ESCC and measure the changes of sensitivity of ESCC cells to cisplatin after cells were treated with mTOR siRNA by WST-8 assays, TUNEL, RT-PCR, and western blots in vitro and in vivo. Cisplatin 184-193 mechanistic target of rapamycin kinase Homo sapiens 224-228 24818169-4 2014 mTOR siRNA significantly increased the sensitivity of the EC9706 cells to cisplatin at proliferation in vitro and in vivo. Cisplatin 74-83 mechanistic target of rapamycin kinase Homo sapiens 0-4 24818169-6 2014 The present study demonstrates that the expression of mTOR has important clinical significance and inhibition of mTOR pathway by mTOR siRNA can improve the sensitivity of ESCC cells to cisplatin. Cisplatin 185-194 mechanistic target of rapamycin kinase Homo sapiens 54-58 24818169-6 2014 The present study demonstrates that the expression of mTOR has important clinical significance and inhibition of mTOR pathway by mTOR siRNA can improve the sensitivity of ESCC cells to cisplatin. Cisplatin 185-194 mechanistic target of rapamycin kinase Homo sapiens 113-117 22488590-6 2013 In addition, clinical PI3K/mTOR inhibitors, PI-103, and BEZ235, showed anti-proliferative effects on BRCA1 mutant breast cancer cell lines and synergism in combination with chemotherapeutic drugs, cisplatin, doxorubicin, topotecan, and gemcitabine. Cisplatin 197-206 mechanistic target of rapamycin kinase Homo sapiens 27-31 24137412-10 2013 The study concludes that miR-199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mTOR and that mTOR may be the target of miR-199a during this process. Cisplatin 53-62 mechanistic target of rapamycin kinase Homo sapiens 130-134 24818169-6 2014 The present study demonstrates that the expression of mTOR has important clinical significance and inhibition of mTOR pathway by mTOR siRNA can improve the sensitivity of ESCC cells to cisplatin. Cisplatin 185-194 mechanistic target of rapamycin kinase Homo sapiens 113-117 23651616-0 2013 Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux. Cisplatin 106-115 mechanistic target of rapamycin kinase Homo sapiens 44-73 23408563-12 2013 Suppressing the Akt/mTOR pathway by the NADPH oxidase inhibitor diphenyl iodonium (DPI) indicated that cisplatin-induced activation of Akt/mTOR pathway requires generation of reactive oxygen species (ROS) through NADPH oxidase. Cisplatin 103-112 mechanistic target of rapamycin kinase Homo sapiens 20-24 24029486-10 2013 Inhibition of GRP78 expression reduced the cisplatin-induced up-regulations of p-Akt and p-mTOR and induced XBP1 mRNA shear expression and CHOP mRNA expression. Cisplatin 43-52 mechanistic target of rapamycin kinase Homo sapiens 91-95 23591341-9 2013 Cisplatin treatment inhibited the phosphorylation of mTOR/P70S6K, which was most significant at the concentration of 100 mumol/L for 48 h. Cisplatin also induced cell viability loss, which was 12% and 45% at the concentrations of 50, and 100 mumol/L for 24 h. This effect could be enhanced by rapamycin (F=74.890,P<0.01). Cisplatin 0-9 mechanistic target of rapamycin kinase Homo sapiens 53-57 23591341-9 2013 Cisplatin treatment inhibited the phosphorylation of mTOR/P70S6K, which was most significant at the concentration of 100 mumol/L for 48 h. Cisplatin also induced cell viability loss, which was 12% and 45% at the concentrations of 50, and 100 mumol/L for 24 h. This effect could be enhanced by rapamycin (F=74.890,P<0.01). Cisplatin 139-148 mechanistic target of rapamycin kinase Homo sapiens 53-57 23408563-12 2013 Suppressing the Akt/mTOR pathway by the NADPH oxidase inhibitor diphenyl iodonium (DPI) indicated that cisplatin-induced activation of Akt/mTOR pathway requires generation of reactive oxygen species (ROS) through NADPH oxidase. Cisplatin 103-112 mechanistic target of rapamycin kinase Homo sapiens 139-143 23128378-9 2013 Furthermore, iNOS gene-mediated enhancement of cisplatin-mediated antitumor effects in lung cancer may be related to the attenuation of p-mTOR, MMP2 and the activation of p-p53. Cisplatin 59-68 mechanistic target of rapamycin kinase Homo sapiens 162-166 23188704-8 2013 Besides, cisplatin treatment activated the mammalian target of rapamycin (mTOR) pathway as shown by increased phosphorylation of Akt1, mTOR, S6K, and 4E-BP1, together with the elevated Livin. Cisplatin 9-18 mechanistic target of rapamycin kinase Homo sapiens 43-72 23188704-8 2013 Besides, cisplatin treatment activated the mammalian target of rapamycin (mTOR) pathway as shown by increased phosphorylation of Akt1, mTOR, S6K, and 4E-BP1, together with the elevated Livin. Cisplatin 9-18 mechanistic target of rapamycin kinase Homo sapiens 74-78 23188704-8 2013 Besides, cisplatin treatment activated the mammalian target of rapamycin (mTOR) pathway as shown by increased phosphorylation of Akt1, mTOR, S6K, and 4E-BP1, together with the elevated Livin. Cisplatin 9-18 mechanistic target of rapamycin kinase Homo sapiens 135-139 22985566-0 2012 [CA916798 gene participates in cisplatin resistance of human lung adenocarcinoma A549 cells through PI3K/AKT/mTOR pathway]. Cisplatin 31-40 mechanistic target of rapamycin kinase Homo sapiens 109-113 23533654-0 2013 Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma. Cisplatin 125-134 mechanistic target of rapamycin kinase Homo sapiens 31-60 23533654-6 2013 Moreover, we found that cisplatin (CDDP) activated PI3K/AKT and mTORC1 pathways and NVP-BEZ235 alleviated the activation by CDDP through dually targeting PI3K and mTOR kinases. Cisplatin 24-33 mechanistic target of rapamycin kinase Homo sapiens 64-68 23533654-6 2013 Moreover, we found that cisplatin (CDDP) activated PI3K/AKT and mTORC1 pathways and NVP-BEZ235 alleviated the activation by CDDP through dually targeting PI3K and mTOR kinases. Cisplatin 35-39 mechanistic target of rapamycin kinase Homo sapiens 64-68 22985566-4 2012 CONCLUSION: CA9167981 gene is located downstream of the PI3K/AKT/mTOR pathway, which might be one of the mechanisms of CA916798 to cause cisplatin resistance in the tumor cells. Cisplatin 137-146 mechanistic target of rapamycin kinase Homo sapiens 65-69 22985566-3 2012 RESULTS: Blocking PI3K/AKT/mTOR pathway with rapamycin and LY294002 significantly reduced drug resistance of both A549 and A549/CDDP cells to cisplatin and obviously decreased the expression of CA916798 gene mRNA (P<0.05). Cisplatin 142-151 mechanistic target of rapamycin kinase Homo sapiens 27-31 22673193-0 2012 Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition. Cisplatin 46-55 mechanistic target of rapamycin kinase Homo sapiens 75-79 22614869-11 2012 Moreover, downregulation of miR-130a could inhibit MDR1 mRNA and P-gp expression and overcome the cisplatin resistance in SKOV3/CIS cells, which indicated that miR-130a may be associated with MDR1/P-gp-mediated drug resistance and plays the role of an intermediate in drug-resistance pathways of PI3K/Akt/PTEN/mTOR and ABC superfamily drug transporters in SKOV3/CIS cells. Cisplatin 110-119 mechanistic target of rapamycin kinase Homo sapiens 358-362 22673193-5 2012 Downregulation of mTOR/S6K1 reduced Mcl-1 protein expression, consequently promoting sensitization to cisplatin. Cisplatin 102-111 mechanistic target of rapamycin kinase Homo sapiens 18-22 22673193-8 2012 In conclusion, silencing of Twist1 sensitizes lung cancer cells to cisplatin via stimulating AMPK-induced mTOR inhibition, leading to a reduction in Mcl-1 protein. Cisplatin 67-76 mechanistic target of rapamycin kinase Homo sapiens 106-110 23056046-8 2012 The results in the present study suggest that genistein could enhance the activity of cisplatin via inhibition of NF-kappaB and Akt/mTOR pathways. Cisplatin 86-95 mechanistic target of rapamycin kinase Homo sapiens 132-136 22294050-2 2012 mTOR inhibition can restore sensitivity to DNA damaging agents such as cisplatin. Cisplatin 83-92 mechanistic target of rapamycin kinase Homo sapiens 0-4 22246235-9 2012 Furthermore, NEFL physically associated with tuberous sclerosis complex 1 (TSC1), a known inhibitor of the mTOR pathway, and NEFL downregulation led to functional activation of mTOR pathway and consequentially conferred cisplatin resistance. Cisplatin 220-229 mechanistic target of rapamycin kinase Homo sapiens 107-111 22246235-9 2012 Furthermore, NEFL physically associated with tuberous sclerosis complex 1 (TSC1), a known inhibitor of the mTOR pathway, and NEFL downregulation led to functional activation of mTOR pathway and consequentially conferred cisplatin resistance. Cisplatin 220-229 mechanistic target of rapamycin kinase Homo sapiens 177-181 22901187-1 2012 OBJECTIVE: The PI3K/PTEN/AKT/mTOR signaling pathway has been implicated in resistance to cisplatin. Cisplatin 89-98 mechanistic target of rapamycin kinase Homo sapiens 29-33 23056575-8 2012 AA005 also inhibits chemotherapeutic agent cisplatin-triggered up-regulation of mTOR and synergizes with this drug in suppression of proliferation and induction of apoptosis of colon cancer cells. Cisplatin 43-52 mechanistic target of rapamycin kinase Homo sapiens 80-84 21764510-1 2011 The present study was performed to investigate the possible role of mTOR inhibitors in restoring chemosensitivity to adriamycin/cisplatin and elucidate the underlying mechanism. Cisplatin 128-137 mechanistic target of rapamycin kinase Homo sapiens 68-72 20214883-0 2010 Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Cisplatin 41-50 mechanistic target of rapamycin kinase Homo sapiens 16-20 20686837-5 2011 Using a validated kinase inhibitor library, we showed that inhibition of the mTOR, TGFbetaRI, NFkappaB, PI3K/AKT, and MAPK pathways sensitized basal-like MDA-MB-468 cells to cisplatin treatment. Cisplatin 174-183 mechanistic target of rapamycin kinase Homo sapiens 77-81 20847160-1 2010 UNLABELLED: Targeting the mammalian target of rapamycin (mTOR) pathway is a potential means of overcoming cisplatin resistance in ovarian cancer patients. Cisplatin 106-115 mechanistic target of rapamycin kinase Homo sapiens 26-55 20847160-1 2010 UNLABELLED: Targeting the mammalian target of rapamycin (mTOR) pathway is a potential means of overcoming cisplatin resistance in ovarian cancer patients. Cisplatin 106-115 mechanistic target of rapamycin kinase Homo sapiens 57-61 20847160-2 2010 Because mTOR inhibition affects cell proliferation, we aimed to study whether 3"-deoxy-3"-(18)F-fluorothymidine ((18)F-FLT) PET could be useful for monitoring early response to treatment with mTOR inhibitors in an animal model of cisplatin-resistant ovarian tumor. Cisplatin 230-239 mechanistic target of rapamycin kinase Homo sapiens 192-196 20847160-12 2010 These data suggest that early treatment monitoring by (18)F-FLT PET may be of use in future preclinical or clinical trials evaluating treatment of cisplatin-resistant ovarian tumors by mTOR inhibitors. Cisplatin 147-156 mechanistic target of rapamycin kinase Homo sapiens 185-189 21050361-12 2011 CONCLUSIONS: mTOR blockade inhibits urothelial carcinoma cell proliferation and enhances the effectiveness of cisplatin. Cisplatin 110-119 mechanistic target of rapamycin kinase Homo sapiens 13-17 21358348-9 2011 Accordingly, cisplatin and temsirolimus exerted synergistic inhibition of the mTOR downstream signals and enhanced growth inhibition and/or apoptosis induction in mesothelioma cell lines. Cisplatin 13-22 mechanistic target of rapamycin kinase Homo sapiens 78-82 19471857-0 2010 The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. Cisplatin 83-92 mechanistic target of rapamycin kinase Homo sapiens 16-20 19853261-12 2010 CONCLUSIONS: Sirolimus appears to enhance the cytotoxicity of cisplatin in malignant pleural mesothelioma cell lines through the mammalian target of rapamycin pathway. Cisplatin 62-71 mechanistic target of rapamycin kinase Homo sapiens 129-158 20214883-2 2010 Here, we show that the Akt/mTOR survival pathway plays an important role in cisplatin resistance in human ovarian cancer cells. Cisplatin 76-85 mechanistic target of rapamycin kinase Homo sapiens 27-31 20214883-3 2010 Specifically, we found that cisplatin treatment activates the Akt/mTOR survival pathway and that inhibition of this pathway by the PI3K inhibitor LY294002 or knockdown of Akt sensitizes ovarian cancer cells to cisplatin. Cisplatin 28-37 mechanistic target of rapamycin kinase Homo sapiens 66-70 20214883-3 2010 Specifically, we found that cisplatin treatment activates the Akt/mTOR survival pathway and that inhibition of this pathway by the PI3K inhibitor LY294002 or knockdown of Akt sensitizes ovarian cancer cells to cisplatin. Cisplatin 210-219 mechanistic target of rapamycin kinase Homo sapiens 66-70 20214883-5 2010 Importantly, inhibition of Akt or mTOR sensitized resistant cells to cisplatin-induced apoptosis. Cisplatin 69-78 mechanistic target of rapamycin kinase Homo sapiens 34-38 20214883-6 2010 Taken together, our data indicate that activation of the Akt/mTOR pathway prevents cisplatin-induced apoptosis, leading to cisplatin resistance. Cisplatin 83-92 mechanistic target of rapamycin kinase Homo sapiens 61-65 20214883-6 2010 Taken together, our data indicate that activation of the Akt/mTOR pathway prevents cisplatin-induced apoptosis, leading to cisplatin resistance. Cisplatin 123-132 mechanistic target of rapamycin kinase Homo sapiens 61-65 20214883-7 2010 Therefore, our study suggests that cisplatin resistance can be overcome by targeting the Akt/mTOR survival pathway in human ovarian cancer cells. Cisplatin 35-44 mechanistic target of rapamycin kinase Homo sapiens 93-97 19690197-0 2009 mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Cisplatin 47-56 mechanistic target of rapamycin kinase Homo sapiens 0-4 19484784-7 2009 mTOR small interfering (siRNA) was transfected into the cell lines, and proliferation and apoptosis were assessed after exposure to cisplatin. Cisplatin 132-141 mechanistic target of rapamycin kinase Homo sapiens 0-4 19484784-11 2009 Cell growth was significantly decreased in cells transfected with mTOR siRNA and treated with cisplatin compared with either alone (CI < 1). Cisplatin 94-103 mechanistic target of rapamycin kinase Homo sapiens 66-70 19690197-0 2009 mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Cisplatin 71-80 mechanistic target of rapamycin kinase Homo sapiens 0-4 19690197-7 2009 Increased expression of phospho-mTOR was observed in cisplatin-resistant RMG1-CR and KOC7C-CR cells, compared with the respective parental cells. Cisplatin 53-62 mechanistic target of rapamycin kinase Homo sapiens 32-36 19690197-8 2009 This increased expression of phospho-mTOR in cisplatin-resistant cells was associated with increased activation of AKT. Cisplatin 45-54 mechanistic target of rapamycin kinase Homo sapiens 37-41 19690197-11 2009 Moreover, mTOR inhibition by RAD001 may be efficacious as a second-line treatment of recurrent disease in patients previously treated with cisplatin. Cisplatin 139-148 mechanistic target of rapamycin kinase Homo sapiens 10-14 19540648-0 2009 Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy. Cisplatin 94-103 mechanistic target of rapamycin kinase Homo sapiens 27-31 19540648-1 2009 OBJECTIVE: This study was to investigate the role of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer development and its mechanism in cisplatin-based chemotherapy. Cisplatin 143-152 mechanistic target of rapamycin kinase Homo sapiens 66-70 19540648-8 2009 Down-regulation of AKT by triciribine or shRNA transfection could attenuate cisplatin resistance through mTOR/Survivin signaling. Cisplatin 76-85 mechanistic target of rapamycin kinase Homo sapiens 105-109 19540648-9 2009 CONCLUSIONS: The PI3K/AKT/mTOR signaling was involved in epithelial ovarian cancer development and cisplatin-based chemotherapy, and down-regulation of AKT could be an effective adjuvant antitumor therapy. Cisplatin 99-108 mechanistic target of rapamycin kinase Homo sapiens 26-30 19240722-6 2009 An activated tumour cell VEGFR2/AKT/mTOR pathway was associated with increased incidence of ascites (chi(2), P=0.002) and reduced overall survival of cisplatin-taxane-based patients with serous histology (N=32, log-rank test, P=0.04). Cisplatin 150-159 mechanistic target of rapamycin kinase Homo sapiens 36-40 20196784-6 2009 Autophagy induction in cisplatin-treated cells was preceded by activation of adenosine monophosphate-activated protein kinase (AMPK) and concomitant down-regulation of mammalian target of rapamycin (mTOR)-mediated phosphorylation of p70S6 kinase. Cisplatin 23-32 mechanistic target of rapamycin kinase Homo sapiens 168-197 20196784-6 2009 Autophagy induction in cisplatin-treated cells was preceded by activation of adenosine monophosphate-activated protein kinase (AMPK) and concomitant down-regulation of mammalian target of rapamycin (mTOR)-mediated phosphorylation of p70S6 kinase. Cisplatin 23-32 mechanistic target of rapamycin kinase Homo sapiens 199-203 20196784-8 2009 Finally, siRNA-mediated AMPK down-regulation and AMPK inhibitor compound C increased cisplatin-induced tumour cell death, while mTOR siRNA and AMPK activator metformin protected tumour cells from cisplatin. Cisplatin 196-205 mechanistic target of rapamycin kinase Homo sapiens 128-132 20196784-9 2009 Taken together, these data suggest that cisplatin-triggered activation of AMPK and subsequent suppression of mTOR activity can induce an autophagic response that protects tumour cells from cisplatin-mediated apoptotic death. Cisplatin 40-49 mechanistic target of rapamycin kinase Homo sapiens 109-113 20196784-9 2009 Taken together, these data suggest that cisplatin-triggered activation of AMPK and subsequent suppression of mTOR activity can induce an autophagic response that protects tumour cells from cisplatin-mediated apoptotic death. Cisplatin 189-198 mechanistic target of rapamycin kinase Homo sapiens 109-113 19058911-9 2009 BCH treatment decreased the phosphorylation of mTOR, p70S6K and 4EBP1, suggesting that BCH enhanced anti-tumor action of cisplatin by inhibiting mTOR pathway. Cisplatin 121-130 mechanistic target of rapamycin kinase Homo sapiens 47-51 19058911-9 2009 BCH treatment decreased the phosphorylation of mTOR, p70S6K and 4EBP1, suggesting that BCH enhanced anti-tumor action of cisplatin by inhibiting mTOR pathway. Cisplatin 121-130 mechanistic target of rapamycin kinase Homo sapiens 145-149 18585380-0 2008 Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. Cisplatin 28-37 mechanistic target of rapamycin kinase Homo sapiens 14-18 18585380-1 2008 We show that cisplatin resistance in certain lung cancer cell lines can be reversed through inhibition of mTOR (mammalian Target of Rapamycin). Cisplatin 13-22 mechanistic target of rapamycin kinase Homo sapiens 106-110 18585380-1 2008 We show that cisplatin resistance in certain lung cancer cell lines can be reversed through inhibition of mTOR (mammalian Target of Rapamycin). Cisplatin 13-22 mechanistic target of rapamycin kinase Homo sapiens 112-141 18585380-3 2008 Interestingly in one cisplatin resistant cell line which expresses BCL2/BCLxL, treatment with mTOR inhibitor (CCI-779) results in decreased levels of these anti-apoptotic proteins and may contribute to increasing apoptosis. Cisplatin 21-30 mechanistic target of rapamycin kinase Homo sapiens 94-98 17616691-9 2007 These studies conclude that AKT amplification and the mTOR pathway play an important role in human lung cancer cells acquiring CDDP resistance, which represents a new mechanism for acquiring CDDP resistance and a potential novel therapeutic target for overcoming CDDP resistance in human cancer in the future. Cisplatin 191-195 mechanistic target of rapamycin kinase Homo sapiens 54-58 20066897-8 2009 Combined cisplatin and rapamycin treatment resulted in significant downregulated p-mTOR and S6K expression, but no change in ERCC1 expression. Cisplatin 9-18 mechanistic target of rapamycin kinase Homo sapiens 83-87 18058806-9 2008 In the in vitro study, cisplatin at CPI(50) targets both the apoptosis and survival pathway by activating the caspase-cascade; inhibiting Akt, mTOR, p70S6K, and 4EBP1. Cisplatin 23-32 mechanistic target of rapamycin kinase Homo sapiens 143-147 18058806-14 2008 Inhibition of the mTOR pathway contributes to cisplatin-induced apoptosis in cervical cancer cell lines. Cisplatin 46-55 mechanistic target of rapamycin kinase Homo sapiens 18-22 17634556-10 2007 RAD001 enhanced cisplatin-induced apoptosis in cells with high AKT/mTOR activity, with minimal effect in cells with low AKT-mTOR activity. Cisplatin 16-25 mechanistic target of rapamycin kinase Homo sapiens 67-71 17616691-0 2007 AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cisplatin 29-38 mechanistic target of rapamycin kinase Homo sapiens 89-118 17616691-8 2007 Our results further showed that AKT1 induced lung cancer cells to become resistant to CDDP through the mammalian target of the rapamycin (mTOR) signaling pathway. Cisplatin 86-90 mechanistic target of rapamycin kinase Homo sapiens 138-142 17616691-9 2007 These studies conclude that AKT amplification and the mTOR pathway play an important role in human lung cancer cells acquiring CDDP resistance, which represents a new mechanism for acquiring CDDP resistance and a potential novel therapeutic target for overcoming CDDP resistance in human cancer in the future. Cisplatin 127-131 mechanistic target of rapamycin kinase Homo sapiens 54-58 17616691-9 2007 These studies conclude that AKT amplification and the mTOR pathway play an important role in human lung cancer cells acquiring CDDP resistance, which represents a new mechanism for acquiring CDDP resistance and a potential novel therapeutic target for overcoming CDDP resistance in human cancer in the future. Cisplatin 191-195 mechanistic target of rapamycin kinase Homo sapiens 54-58 16786123-11 2006 Moreover, the expression of phosphorylated mTOR may have a role as a marker to predict response to chemotherapy and survival of cervical cancer patients who are treated with cisplatin-based neoadjuvant chemotherapy. Cisplatin 174-183 mechanistic target of rapamycin kinase Homo sapiens 43-47